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Human Herpes virus-8 (HHV-8) is the known etiologic agent for several 
malignant pathologies, including Kaposi’s sarcoma (KS), the most common tumor in 
children in sub-Saharan Africa. Saliva is implicated as the culprit of transmission; 
however there is a paucity of information regarding transmission to young children. In 
this study, we investigated the hypothesis that household behaviors exposing the 
susceptible child to saliva increase the risk of transmission of HHV-8 to that child. 
To test our hypothesis a large prospective cohort study in Lusaka, Zambia, 
enrolling 464 young children and their households, was followed for 48 months.  Socio-
demographics, health histories, feeding and child-rearing behaviors were assessed. 
At enrollment, 75 HHV-8 positive children were analyzed for existing risk factors 
contributing to HHV-8 seropositivity.  Analysis for independent variables found that for 
each additional HHV-8 positive household member, there was 2.5 greater odds for the 
child to be HHV-8 positive (P < 0.01).   Of the household saliva sharing risk behaviors, a 
primary caregiver testing temperature of food prior to feeding to a child posed a 2.4 
greater odds (P = 0.01). A child having been breastfed offered a decreased risk (OR 0.3, 
P < 0.01).    
Of the enrolled children, 270 children were available for longitudinal analysis.  Of 
these, 137 children seroconverted to become HHV-8 positive, an incidence of 29.94 per 
  
100 child-years.  Most significant independent behavioral risk factors for HHV-8 
seroconversion included increased risk with current breastfeeding (HR 2.1, P = 0.002), 
increased risk with use of pacifier (HR 9.0, P = 0.01), and greater risk with household 
members blowing on food prior to sharing with child (HR 2.8, P = 0.05).  Other studies 
in this report include development of an HHV-8 serodiagnostic assay.     
Taken together, this report describes the epidemiology of HHV-8 transmission to 
a susceptible child within households, and the association with saliva sharing behaviors. 
Our results support the need for increased public awareness and education regarding risks 
of viral transmission with child-rearing behaviors that expose the child to saliva. 
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CHAPTER 1: LITERATURE REVIEW 
THE HERPESVIRUSES 
The Herpesviridae is one of the largest families of viruses, with more than 100 
members isolated from almost all mammalian species (reviewed in [1]). Assignment of a 
virus into the herpesvirus family is based on morphology of the virus particle and 
genomic similarity. Under an electron microscope, the virions of different members of 
the Herpesviridae family are indistinguishable. Each consists of four well-defined 
components including the core, capsid, tegument, and envelope. The core contains a 
double-stranded DNA genome, which is located inside an icosadeltahedral capsid that is 
approximately 100 nm in diameter and contains 162 capsomeres (reviewed in [1]). A 
layer of proteins collectively known as the tegument is located between the capsid and 
the viral envelope. The variation in size of mature herpes viruses (120 to 300 nm) is 
mostly due to differences in the size of the individual viral teguments. The tegument 
arrangement is typically asymmetrical with some herpetic members showing less 
ambiguous tegumental structures than others. Structurally the tegument connects the 
capsid to the envelope, while functionally acting as a reservoir for viral proteins which 
are required during the initial phases of viral infection [2]. Several herpesviral tegument 
proteins have been shown to play a role in evading the host immune response. For 
example, the p65 protein of human cytomegalovirus blocks the presentation of viral 
immediate-early proteins by MHC class I molecules, and interferes with NK cell 
responses by interacting with an NK cell-activating receptor [3]. 
The outermost framework of the herpes virion is the envelope, which is derived 
from cell nuclear membranes and is impregnated with various viral glycoproteins. By 
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interacting with cellular receptors during early phases of infection, these glycoproteins 
help to determine host range of specific herpesviruses. All herpesvirus infections have a 
limited cellular tropism within their specific host, determining their sites of infection and 
latency. Most herpesviruses recognize multiple cellular receptors, and the majority makes 
initial contact with cells by binding to glycosaminoglycans such as heparin sulfate on the 
cell surface, followed by interaction with other specific cellular receptors [4].   
Some important herpesviruses of domestic animals include Suid herpesvirus 1, 
the cause of pseudorabies; bovine herpesvirus 1, the cause of infectious bovine 
rhinotracheitis; feline herpesvirus 1, the cause of feline viral rhinotracheitis; and equine 
herpesviruses, which can cause diseases of the respiratory, reproductive, and nervous 
system of horses. Marek’s disease of chickens is caused by an oncogenic herpesvirus that 
can cause T cell lymphomas, along with other syndromes [5].   
Eight viruses in the family Herpesviridae are of specific interest because of their 
capability to cause disease in humans (see table 1).  Clinically significant human 
herpesviruses include the herpes simplex viruses (HSV-1 and HSV-2), varicella zoster 
virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), and Kaposi’s sarcoma-
associated herpesvirus (KSHV), also known as HHV-8.   
HERPESVIRUS CLASSIFICATIONS 
Herpesviruses have been classified into three subfamilies, α, β and γ, by the 
Herpesvirus Study Group of the International Committee on the Taxonomy of Viruses.  
Membership into a particular subfamily is based on its biologic properties.  See Table 1 
for short description of the herpesvirus subfamilies, associated diseases in humans, 
cellular tropism and the means of transmission in humans. Although classification does 
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not rely on DNA sequence homology, sequence analysis of the DNA polymerase gene 
and the glycoprotein B gene have allowed researchers to identify and appropriately 
characterize the viral subfamilies [6]   
Alphaherpesviruses     
The alphaherpesvirinae subfamily is divided into two genera; Simplexvirus, 
which includes herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2) and 
Varicellovirus, which includes varicella-zoster virus (VZV), also called human 
herpesvirus-3 (HHV-3).  Alphaherpesviruses are known for causing painful fluid-filled 
epithelial vesicular lesions, HSV-1 is the causative agent for oro-facial fever blisters, also 
known as common cold sores.  The primary route of HSV-1 transmission is via saliva; 
however it can also be transmitted via an oro-genital route, causing genital lesions [7, 8].  
HSV-2 is known as a sexually transmitted disease, responsible for genital herpes. A risk 
of transmission to newborns also exists correlating to maternal viral shedding at delivery 
(reviewed in [8]).  VZV causes varicella (chicken pox), and herpes zoster (shingles).  
After primary infection (chicken pox syndrome), VZV maintains latency in sensory 
ganglia and can reactivate later in life, producing herpes zoster [9].    
Alphaherpeviruses have a short replicative cycle in the host, grow and spread 
rapidly in cell culture, and share the establishment of latent infections in sensory ganglia.  
Members of this subfamily are often referred to as neurotropic herpes viruses [6].   
Betaherpesviruses 
The betaherpesvirinae subfamily consists of two genera; Cytomegalovirus, which 
includes human herpesvirus-5 or cytomegalovirus (CMV), and Roseolovirus, which 
includes human herpesvirus-6 (HHV-6A and HHV-6B) and human herpesvirus-7 (HHV-
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7).  HHV-6 and HHV-7 are ubiquitous in the general population, but cause disease in 
immunocompromised patients and in infants.  The disease Exanthema subitum, also 
known as roseola infantum can be caused by both HHV-6 strains and HHV-7 [10].  This 
disease occurs in young children and is characterized by a generalized macular or popular 
rash on the face or trunk, accompanied by high fever [11].  Although usually mild, 
convulsions and encephalopathy may accompany the infection [12].   
CMV is considered to be ubiquitous in adults, and infection can be unnoticed in 
healthy individuals.  However life threatening diseases can develop for immune 
compromised individuals infected with CMV, such as HIV-positive individuals, organ 
transplant recipients, and newborn infants [13].  Congenitally acquired CMV is perhaps 
the most clinically significant form, resulting in infant mortality or permanent disabilities 
such as hearing loss and developmental disabilities (reviewed in [14]).  CMV 
transmission is known to occur via the sexual route in adults, (reviewed in [14]), and 
through breastfeeding to young children [15]. 
Betaherpesviruses have a fairly restricted host range, with a long reproductive 
cycle, both in cell culture and within the infected host. These viruses are cytopathic in 
culture; infected cells demonstrate morphological changes and cytomegalia (cellular 
enlargement) [6].      
Gammaherpesviruses 
The gammaherpesvirinae subfamily includes HHV-8 and human herpesvirus-4 
(HHV-4) or Epstein-Barr virus (EBV), the only other gamma herpesvirus infecting 
humans. Gammaherpesviruses have a restricted host range, viral replication generally 
restricted to either T or B-cell lymphocytes, and latent infections in lymphoid tissues [6].   
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The gammaherpesviruses subfamily contains two genera, Lymphocrptovirus 
(LCV) (gamma-1), and Rhadinovirus (RDV) (gamma-2).  EBV is the only LCV and 
HHV-8 is the only RDV discovered known to infect humans. LCV is found only in 
primates, but RDV can be found in both primates and other mammals [6]. 
EPSTEIN BARR VIRUS 
 Epstein-Barr virus is implicated in numerous clinical diseases, including 
infectious mononucleosis, Burkitt’s lymphoma, Hodgkin’s disease, B-
lymphoproliferative disease, nasopharyngeal carcinoma, and oral hairy leukoplakia.  
There is a well-established relationship between EBV and oncogenesis.  Several genes 
encoded by EBV are essential for inducing transformation of B cells, including EBNA-1, 
EBNA-2, EBNA-3A, EBNA-3C and LMP-1 [16].  The cellular transformation is a 
complex process, involving cooperative interactions between several viral proteins, 
however the pathogenesis is thought to also include genetic aberrations, as occurs in 
Burkitt’s lymphoma in which the c-myc gene is translocated [17]. 
Epstein-Barr virus routes of transmission have been well established, and serve as 
a prototype when studying HHV-8 transmission.  Viral DNA is readily isolated in saliva 
and salivary exchange is the accepted mode of transmission for EBV.  Transmission 
occurs via intimate kissing, sharing drinking glasses, and children sharing of toys.  Viral 
shedding in saliva has been demonstrated to persist for an extended length of time post 
infection.  Fafi-Kremer et al. (2005) demonstrated that in patients evaluated after 
infectious mononucleosis, EBV viral DNA persisted for 6 months post disease onset, 
whereas viral load decreased considerably from PBMC’s and rapidly disappeared from 
plasma [18].   
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HUMAN HERPESVIRUS-8 
 HHV-8 is the most recently discovered human herpesvirus family member, the 
etiologic agent for Kaposi’s sarcoma (KS).  HHV-8 was initially isolated from KS lesions 
in patients with acquired immunodeficiency syndrome (AIDS) using representational 
difference analysis [19].  This virus was further characterized using an infected B-cell 
line derived from an AIDS-related lymphoma patient and a genomic library made from a 
KS lesion to be a gamma-2 herpesvirus [19, 20].  
HHV-8 has sequence homology and genomic organization that is similar to both 
EBV and another well-known Rhadinovirus, herpesvirus saimiri, a T-cell tropic virus 
known to cause lymphoma in primate hosts such as squirrel monkeys, but also has many 
unique sequences [19, 21].   
 Strain variation has been found among HHV-8 isolates.  Five HHV-8 variants 
(groups A to E) have been identified based on analysis of gene products from two HHV-8 
genes, ORF-K1 and ORF-15. Groups A and C predominate in Europe and North 
America, B is dominant in Africa, D and E are found in the Pacific Islands and 
Amerindian populations (reviewed in [22]).   
HHV-8 Genome organization 
 The HHV-8 viral DNA genome consists of a single, long, unique region 
containing all the coding regions and is similar to the genome of herpesvirus saimiri.  The 
coding region is flanked by variable numbers of direct terminal repeats.  HHV-8 
possesses approximately 26 core genes, which are highly conserved across the alpha-, 
beta-, and gammaherpesviruses.  These genes are responsible for gene regulation, 
nucleotide metabolism, DNA replication, and virion maturation and structure (reviewed 
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in [1]).  HHV-8 also has at least 12 human host gene homologs, not shared by other 
human herpesviruses. Some of these genes retain host function, or have been modified 
and implicated in oncogenesis.  These include genes encoding viral Bcl-2, cyclin D, 
interleukin-6, G-protein-coupled receptor, and ribonucleotide reductase [23] (reviewed in 
[1]).  In addition HHV-8 has a number of genes and regulatory proteins that interact with 
the host immune response, functioning in evasion of host cellular defense mechanisms 
[24]. 
Latent phase of infection 
A hallmark of all herpesviruses is that after infecting a host cell, herpesviruses 
cycle between two phases: lytic and latent.  HHV-8 generally enters the lytic cycle 
immediately following primary infection, and then rapidly enters the latent phase.  In the 
latent phase, the viral genome assumes a circular conformation known as an episome.  In 
the latent phase, viral replication is suppressed, resulting in the formation of a quiescent 
state of dormancy, with which minimal gene expression occurs. HHV-8 is able to 
establish a predominantly latent, life-long infection in host monocytes, dendritic cells, B 
lymphocytes, and endothelial cells.  
As with EBV, infection of B cells by HHV-8 triggers the expression of several 
latency-specific genes.  These genes encode proteins that function primarily in the 
maintenance of episomal viral genome in latently infected cells to transform the cells to 
ensure the long-term survival in a short-lived cell.  Latently expressed genes include 
ORF71, which encodes a homologue of the antiapoptotic factor vFLIP, and ORF73, the 
latent nuclear antigen (LANA) which functions to maintain genome integrity and 
episomal persistence [25].    
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Lytic phase of infection 
 For viral propagation to occur, the virus should undergo reactivation from the 
latency into the lytic phase, when active viral replication occurs and newly synthesized 
virions are released into the extracellular space.  The herpesvirus lytic replicative phase 
can be divided into four phases, immediate early (IE), early (E), partial late, and late, 
depending on the transcription pattern prior or after lytic life cycle induction (reviewed 
in[1]). 
Immediate-early (IE) or α genes require no prior viral protein synthesis.  These 
genes are involved in transactivating transcription from other viral genes.  The most 
notable HHV-8  IE gene, ORF50 encodes R transcriptional activator (Rta), which 
functions in the earliest phases of reactivation from latency into the lytic cycle [25]. 
Early or β genes, are expressed independently of viral DNA synthesis.  Encoded 
by K2, vIL-6 is a homolog to the cellular IL-6, and stimulates multiple cellular pathways 
to induce cell proliferation, immunomodulation, and anti-apoptotic activity [26].  
Polyadenylated nuclear (PAN) RNA stabilizes unspliced transcripts, increasing the 
abundance of RNA in the nucleus and blocking the assembly of mRNA-protein 
complexes [27]. 
Partial late or γ1 genes are expressed in concert with the beginning of viral DNA 
synthesis.  This is a subset of late genes, and their transcription rate is enhanced during 
DNA synthesis.  ORF18, which encodes a transfactor that is essential for late gene 
transcription of gammaherpesviruses, is considered to be a γ1 gene [28]. 
Late or γ2 gene expression is totally dependent upon synthesis of viral DNA.  
Virion structural genes encoding for capsid proteins and envelope glycoproteins are 
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considered as late genes.  K8.1 is a late gene that encodes a viral envelope glycoprotein at 
a late phase of infection [29].  
HHV-8 immune responses 
Neutralizing antibody (nAb) responses against HHV-8 have been investigated in 
several systems. A 2004 study compared levels of HHV-8 infection in dermal 
microvascular endothelial cells after incubation with serum from HHV-8 seropositive 
individuals, versus HHV-8 negative controls. Using an indirect immunofluorescence 
assay, these investigators reported significant inhibition of HHV-8 by seropositive sera 
diluted at 1:10 or 1:50, but not at 1:500. Depletion of the IgG fraction of the seropositive 
sera by protein A resulted in a loss of the HHV-8 neutralizing activity [30].  
 Another group reported similar results using HHV-8 infectivity assays on293 
cells, and also found that patients with KS had significantly lower nAb titers compared to 
other HHV-8 infected groups, suggesting a possible role for nAb in protecting against 
progression from latent HHV-8 infection to KS [31].  In contrast, Inoue et al. (2004) 
found no significant difference in the levels of nAbs in HHV-8 positive individuals with 
KS (24%) compared to those without KS (31%) [32]. 
 Because of the association between HIV and HHV-8, several studies have 
explored the question of whether CD4+ T cell levels influence immune responses to 
HHV-8.  Among HIV-infected individuals, Kimball et al. (2004) reported that those with 
KS had lower CD4+ T cell counts and higher levels of anti-HHV-8 antibodies than those 
without KS [31].  This suggests that HHV-8 replication may be limited by CD4+ T cell 
activity.  Another study similarly found that HHV-8 infected people with declining CD4+ 
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T cell counts were associated with increasing antibody reactivity against the HHV-8 Orf 
65 minor capsid antigen [33]. 
 HHV-8 infection also stimulates cytotoxic T lymphocyte (CTL) responses.  A 
1999 study demonstrated that seven out of seven HHV-8 positive, KS negative 
individuals exhibited  MHC class I-restricted CTL-activity against three HHV-8 antigen, 
the K8.1 and K1 lytic proteins, and the K12 latent protein.  In contrast, only two of six 
HHV-8 positive individuals with KS had detectable CTL responses against these 
antigens.  In one patient, whose KS had resolved under HAART therapy, CTL activity 
was restored [34].  In an investigation of HIV-negative subjects that seroconverted to 
HHV-8, Wang et al. (2001) observed distinct CD8+, HLA class I restricted responses and 
increases in the interferon-gamma (IFN-γ) response to at least three of five lytic HHV-8 
antigens in each of the five subjects.  They also observed that CTL reactivity declined 
after several years, probably as HHV-8 entered a more latent state after primary infection 
[35]. 
Immune modulation by HHV-8  
As is the case for all herpesviruses, one of the major immune evasion strategies 
used by HHV-8 is the establishment of latency, during which the majority of viral genes 
are not expressed. This allows the virus to “hide” from most host immune mechanisms 
during this part of its replication cycle. When the virus is in the lytic phase, however, 
other active mechanisms of immune evasion take place. Of the 86 genes encoded by the 
HHV-8 genome, at least 22 may have immunomodulatory effects [36].  
As part of innate immunity, the complement system may play a role in early 
defenses against HHV-8. The ORF4 gene of HHV-8 encodes a protein called KSHV 
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complement-control protein (KCP), also called kaposica, which inhibits complement 
activation by two separate mechanisms [37]. KCP accelerates the decay of the C3 
convertase enzyme complex generated by the classical pathway of complement 
activation, and it also acts as a cofactor for factor I-mediated inactivation of C3b and 
C4b.  
HHV-8-associated diseases, especially KS, are associated with alterations in 
secretion of a variety of cytokines. An early component of innate immune responses to 
viruses is the secretion of type I interferons (IFNs). Cellular responses to type I IFNs 
involve the IFN-regulatory factor (IRF) family of transcription factors, which increases 
expression of MHC class I molecules and activates NK cells. HHV-8 encodes four vIRF 
genes with homology to cellular IRFs [23, 38]. These vIRF proteins (vIRF-1, -2, -3, and -
4) generally inhibit the activities of various cellular IRFs, plus they may have other 
immunomodulatory activities, such as suppression of the IFN-induced, double-stranded 
RNA-activated protein kinase R (PKR) [39] and inhibition of Fas ligand (CD95L) 
expression [40].  
As mentioned earlier in this review, tegument proteins of herpesviruses can also 
be involved in immunomodulation. An example of this is the HHV-8 ORF45 (tegument) 
protein, which blocks phosphorylation and nuclear translocation of IRF-7 [41, 42]. The 
introduction of the ORF45 protein into the cell as part of the virion ensures that it is 
active at the very earliest phases of infection, when deregulating IRF-7. The inactivation 
of cellular IRF-7 seems to be a key event in HHV-8 replication, as evidenced by the 
observation that the HHV-8 replication and transcription activator (RTA) protein, which 
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regulates the switch between latency and lytic replication, also negatively regulates IRF-7 
by targeting it for proteasome-mediated degradation [43].  
HHV-8 also encodes a homologue of human IL-6. IL-6 is normally synthesized 
by mononuclear phagocytes, vascular endothelial cells, and other cells in response to 
microbial infection and to other cytokines. Binding of IL-6 to the IL-6 receptor can have 
several effects, including the synthesis of acute-phase proteins, stimulation of B 
lymphocytes, and upregulation of apoptotic antagonists such as BCL-XL [44]. In 1996, 
Moore et al. reported the discovery of a HHV-8 homologue of IL-6 (vIL-6) which shares 
25% identity with the human cytokine [45]. In some infected individuals, secretion of 
vIL6 may contribute to HHV-8-associated MCD and perhaps PEL by promoting cell 
survival, driving proliferation and preventing apoptosis [46].  
Due to the central role of CTLs in eliminating virus-infected cells in an MHC 
class I-dependent manner, a large number of viruses interfere with presentation of 
cytosolic antigens by MHC class I molecules. This is especially true for viruses, such as 
herpesviruses, that establish persistent or latent infections, [47]. HHV-8 encodes two 
proteins named modulator of immune recognition 1 and 2 (MIR1 and MIR2) [48]. During 
lytic replication, these proteins increase endocytosis of surface MHC class I molecules, 
leading to their degradation in endolysosomes [49-51]. This mechanism differs from 
other known viral inhibitors of MHC class I expression, which interfere with the 
synthesis or assembly of MHC class I chains or retain them in the ER [47]. HHV-8 MIR2 
also reduces surface expression of at least two key molecules involved in T cell function-
-B7-2 (CD86) and ICAM-1 (CD54). B7-2 is an important T cell costimulatory molecule 
that expressed by antigen-presenting cells, and ICAM-1 is an intercellular adhesion 
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molecule that interacts with LFA-1. Therefore, MIR2 not only inhibits the MHC-
dependent presentation of antigen to T cells, but also interferes with other cellular 
interactions that are essential for proper T cell function [49].  
A more recently described immune evasion strategy employed by HHV-8 is a 
modification or reshaping of the host cell receptors for natural killer (NK) cells [24].  
Natural killer cells are known for their ability to directly lyse infected cells and secretion 
of cytokines which limit viral replication, therefore playing a key role in early control of 
viral infections.  Dupuy et al. (2012) described the capability of HHV-8 in decreasing 
expression of NKp30 and NKp46, both which are cellular receptors responsible for 
activating NK cells.  Also demonstrated was a down-regulation of the inhibitory receptor 
CD161.  It has been suggested that the loss of this receptor might result in the 
accumulation of a population of NK cells with a lower activation threshold, which could 
lead to the elimination of activated dendritic cells, establishing a defective antiviral 
adaptive response [24].     
Epigenetics 
Epigenetics refers to modifications of DNA that affect gene expression, with no 
change in nucleotide sequence. Epigenetic influences on disease have become an 
important area of study in understanding factors that play a critical role in disease 
development.  Transcription of a gene is controlled by local chromatin structure.  
Epigenetic modifications to the chromatin structure, either by changes to histones, or the 
DNA strand itself, can change gene expression. Epigenetic modifications mostly include 
chromatin remodeling, histone acetylation, and DNA methlyation.  These all induce 
changes in gene expression that may persist even after removal of the initiating agent, 
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creating the potential to influence the health of future generations. One of the most 
notable studies of epigenetics and disease was completed by Kaati et al. (2002).  They 
found by examining paternal grandfathers who experience a shortage of food at a critical 
time in their growth and development, presented a decreased risk of death from 
cardiovascular disease or diabetes in their grandchildren [52].  These findings suggest 
that diet can cause changes to genes that are inheritable and these alterations can affect 
susceptibility to certain diseases.  
Oncogenic viruses are known to cause epigenetic modification.  An example of 
DNA methylation and implication in oncogenesis is seen in EBV.  The EBV latency-
associated virus gene products in B cells lead to epigenetic repression and CpG 
methylation of the pro-apoptotic gene Bim, inhibiting tumor suppression [53].  HHV-8 is 
considered to be an oncogenic virus, in which its ability to maintain latency is implicated 
in its oncogenesis. Chromatin remodeling and demethylation of the HHV-8 lytic switch 
gene Rta (ORF50) promoter, controls viral lytic phase entry; hyperacetylation of the 
latent replication origin controls latent cycle replication [54].  This switch between latent 
and lytic phases of HHV-8 infection leads to active viral replication, cellular 
transformation, or oncogenesis.  In most primary effusion lymphoma (PEL) cell lines, 
HHV-8 is in the latent phase, but the lytic cycle can be induced by treatment with the 
DNA methyltransferase inhibitor 5-Azacytidine (5-AzaC), the HDAC inhibitor sodium 
butyrate (NaB), and the HAT inducer tetradecanoylphorbol acetate (TPA) [55, 56].  Chen 
et al. (2001) also showed that treatment with 5-AzaC, and therefore demethylation of the 
HHV-8 Orf50 promoter, caused lytic reactivation accompanied by IE, early, and late 
gene expression [55].  Orf50/RTA expression may be activated by physiological 
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conditions, such as hypoxia, or pharmaceutical agents, leading to viral replication and 
disease pathogenesis [57, 58]. 
This reprogramming of host cell DNA has important implications not only for 
understanding viral persistence and pathogenesis of herpesviral associated diseases, but 
also has potential significance in epidemiology and transmission. In transmission studies, 
this potential influence of epigenetics raises many questions.  What are these changes, 
and how does the environment play a role?  When considering viral pathogenesis, it is 
especially interesting to determine if the epigenetic influence on disease may also be an 
influencing factor on risk of transmission.    
Epigenetic initiators are not well defined, but in human disease, many different 
environmental influences have been implicated as sufficient to initiate epigenetic 
changes, such as stress, diet, hormones, toxins, ageing, and genetic influences [59].  All 
of these influences may play a role in viral ability to infect, persist, and replicate, and 
therefore help explain populations at risk for disease, as well as potentially transmission.   
Pathogenic Mechanisms of HHV-8  
HHV-8 is considered to be an oncogenic virus because of its involvement in 
cancer related etiologies such as B-cell lymphomas, and Kaposi’s sarcoma (KS).  Much 
of the pathogenic mechanisms of HHV-8 has been learned from studying KS 
development.  The classic hallmark of KS tissue is the appearance of characteristic 
spindle shaped cells.  Early histochemistry and ultrastructural studies revealed that 
proliferating KS spindle tumor cells are of endothelial origin, confirmed by more recent 
use of genomic technologies [60, 61].  Circulating blood mononuclear and endothelial 
“Progenitor cells” when infected with HHV-8 are reprogrammed to resemble lymphatic 
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endothelium, which upregulates several lymphatic associated genes such as lymphatic 
vessel endothelial receptor 1 (LYVE1) podoplanin, and vascular endothelial growth 
factor receptor 3 (VEGFR3) [62] (reviewed in [61]). 
Worldwide, HHV-8 seroprevalence far exceeds the incidence of KS.  This 
indicates that HHV-8 infection alone appears to be insufficient for the development of 
KS, suggesting that other cofactors are involved in the causal association, such as 
epigenetic initiators as discussed earlier, co-morbidities, or host immune suppression.  Of 
most significance, is the apparent reliance of KS progression on host immune dysfunction 
and the local inflammatory milieu. HHV-8 encodes a variety of gene products, some 
involved in  cell survival processes such as transformation, proliferation, cell signaling, 
antiapoptosis and angiogenesis, and involvement in immune modulation, including 
cytokine production, and immune evasion [60, 63].  All these mechanisms may be 
involved in the promotion of oncogenesis and viral persistence.   
Diseases caused by HHV-8 
HHV-8 was first identified in 1992 by Chang and Moore (1994) in a biopsy of an 
endothelial tumor lesion from an AIDS patient [19].  HHV-8 has currently been 
determined to be the causative agent in distinctive pathologies: Kaposi’s sarcoma (KS), 
body cavity-based B-cell lymphoma (BCBL), primary effusion lymphoma (PEL), and 
multicentric Castleman’s disease.  
Kaposi’s Sarcoma  
Kaposi’s sarcoma (KS) is an atypical form of cancer that develops in supportive 
connective tissue such as cartilage, bone, fat, muscle, blood vessels, and fibrous tissue. 
Histopathologically, the lesions are classified as endothelial neoplasms containing not 
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only the primary neoplastic proliferating spindle-shaped cells of endothelial origin, but 
also an abundance of extravasated erythrocytes and infiltrating inflammatory cells. KS 
was first described in 1872 by the Hungarian dermatologist, Moritz Kohn Kaposi, as a 
relatively uncommon tumor of very limited prevalence found almost exclusively in 
elderly men of Italian or Eastern European Jewish ancestry [64]. Years later, another 
epidemiological form was reported in young adult and prepubescent equatorial black 
Africans. In 1969, a third form of KS was documented as associated with 
immunosuppressant therapy. However, it was not until 1982 when a sudden increase in 
the prevalence of KS cases, affecting a large variety of individuals who were not 
previously associated with any known epidemiological cluster, that KS began to elicit 
amplified concern in the medical community. This novel form of KS was much more 
aggressive, with a clinical course often characterized as disseminating and fulminating. 
Eventually it was linked to a disease model later denoted as acquired immunodeficiency 
syndrome (AIDS).   
These separate manifestations of KS tumors have been shown to be essentially 
identical from the histopathological standpoint.  However clinical symptoms, age and the 
course of the disease are distinguishable from each other, leading to classifications 
designated as classic, endemic, AIDS-associated, and iatrogenic.  
Classic Kaposi’s Sarcoma 
The terms classic, Mediterranean, and sporadic KS all refer to the same form of 
KS. This is a rare cancer demonstrating ethno-geographical predominance in Eastern 
Europe, and the Mediterranean region with high incidence in Italy, Turkey, Greece, and 
Israel [65].  Classic KS historically has an ethno-geographical predominance in the 
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Mediterranean region, with up to a 10-fold higher incidence than in the rest of Europe 
and the United States (U.S.).  In general, the average onset of the disease is between forty 
to seventy years of age, predominantly occurring in men with sex ratios estimated to 
range from 3:1 to 10:1 [61, 66]. Classic KS tumors are described as one or more 
asymptomatic lesions that occur in the dermal layer of the skin and appear as either 
brown, blue, purple, or red blotches or nodules. The lesions are usually localized to one 
or both lower extremities and frequently involve the ankles and soles of feet, but mucosal 
and visceral lesions may develop [61, 65].  Mortality rates for classic KS are low, and 
although the skin lesions are normally disfiguring, they often are not disabling. Kaposi’s 
sarcoma lesions can persist for ten to fifteen years, with indolent growth of primary 
tumors and a gradual slow growth of additional lesions.  Complications most commonly 
seen include venous congestion and dependant pedal edema secondary to the slowing of 
circulation caused by physical pressure from local tumor infiltration, and infiltration of 
surrounding tissues and lymphatics [67].    
In chronic cases, visceral lesions can develop in lymph nodes, along the 
gastrointestinal tract, and in other organs. Generally, these lesions are asymptomatic, 
most often discovered only at autopsy, although gastrointestinal bleeding can occur [67, 
68].  
Endemic Kaposi’s sarcoma 
In some equatorial countries of Africa, KS has existed for several decades, 
documented as early as 1953 as a relatively commonly occurring neoplasm in native 
populations [69].  This form of KS is known as endemic KS, and reflects the KS disease 
that exists in Africa, not associated with the HIV/AIDS epidemic.  From 1968 to 1970, 
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KS was associated with approximately 6.6% of all cancers seen in Ugandan males, 
reflecting endemic KS incidence prior to the HIV epidemic [70].  The epidemiology 
differs than that of classic KS in the population demographics.  The median age of classic 
KS is 65 years, but the median age of endemic KS is 40 years.  The disease is also seen in 
both children and adults, with a higher male to female ratio of 15:1 (reviewed in [71]).   
Two forms of endemic KS have been described; a local aggressive form and a 
more rare lymphadenopathic form.  The local aggressive form is very aggressive, 
characterized by granulating chancroid sores and a fungating tumor that can penetrate 
from the skin to the underlying bone [72].   The lymphadenopathy form is less frequent, 
and develops primarily in prepubescent children [63].   The generalized lymphatic 
involvement in the lymphadenopathic form is usually associated with visceral organs, and 
is very aggressive [61].  In these cases, a 100% fatality rate within three years of 
diagnosis has been reported [73]. 
Transplant-Immunosuppressive Therapy-Related Kaposi’s sarcoma 
Kaposi’s sarcoma that develops due to the immunosuppressive therapy prescribed 
for post-transplant patients to prevent graft rejection is referred to as immunosuppression-
associated or iatrogenic KS.  Post-transplant KS can result in rejection of the graft and 
death of the patient [26].  Penn et al. conducted a study of 356 pot-transplant patients 
with KS.  Of these 40% had visceral involvement and 17% of these died due to KS [26].  
The risk of KS associated with transplants is exemplified by iatrogenic KS 
prevalence rates of 500 to 1,000-fold higher in solid-organ transplant recipients than in 
the general population, with 46% of all cases developing in the first year [74, 75].  Risk 
varies geographically, ranging from 0.4% of transplant patients in the U.S. and Western 
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Europe, to 5.3% of renal transplant patients in Saudi Arabia [26, 76].  This ethno-
geographic variation reflects the HHV-8 seroprevalance in the general population of 
different countries [26].  
Iatrogenic KS appears more frequently in renal transplant patients as compared to 
other grafted organs (reviewed in [1]).  Presumably this is due to the types of drugs used 
frequently in kidney transplant patients, including cyclosporine, which was demonstrated 
to reactivate HHV-8 in vitro [77, 78].  The influence of cyclosporine was demonstrated in 
a study in which eight of eleven iatrogenic KS patients had complete regression of 
visceral and cutaneous tumor progression within six months of cessation of cyclosporine 
[79].  
AIDS-Related Epidemic Kaposi’s sarcoma 
The beginning of the AIDS epidemic was ushered in by the appearance of a 
fulminant and disseminated form of KS, first observed in U.S. immuno-compromised 
homosexual males in 1981 [80-82]. Subsequently, KS became the most common 
neoplasm occurring in patients with AIDS [77]. 
The underlying cause of AIDS was determined in 1985, originally named the T 
cell leukemia type III virus, later to be renamed the human immunodeficiency virus 
(HIV) [83-85]. HIV infects CD4 + cells, leading to cell death.  The resulting immune 
dysregulation results in an immune-compromised state that predisposes the host to a 
variety of opportunistic infections and neoplasms, including KS.   
AIDS-KS is a much more aggressive tumor than the other forms of KS and can 
disseminate into the viscera with higher mortality rates [86].  The aggressive nature of 
AIDS-KS has been hypothesized to be due to the HIV encoded protein, Tat.  Tat is a 
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transactivator of HIV viral genes, and also some host cell genes.  Tat can act 
extracellularly, inducing angiogenesis and inflammation in endothelial cells, contributing 
to KS pathogenesis (reviewed in [87]). 
  As with the other forms of KS, AIDS-KS has different associated risks among 
HIV positive individuals.  In Western countries including the U.S., AIDS-KS 
predominantly is found in HIV positive homosexual or bisexual men, and less commonly 
in heterosexual individuals [77]. Studies in the U.S. have shown that HIV-infected 
homosexual men have a greater than 10,000 times risk of developing KS than the general 
population [88]. 
The impact of the AIDS epidemic on incidence rates of KS in African countries 
has been significant. The increase in incidence does not exhibit the same gender and 
sexual orientation preference exhibited in developed countries, with increased incidence 
rates in both men, and women, as well as in children.  In Uganda, KS accounted for 
approximately 6.6% of all cancers prior to the onset of the AIDS epidemic; however data 
compiled from 1981-91 attributed 48.6% of all cancers in males, making it the leading 
cancer in males.  In women, during this same time period, KS was the second most 
frequent cancer, at 17.9%.  In children KS increased by an additional 40% [70]. AIDS-
related KS risk associations in Africa include better education, an affluent life style, 
urban as opposed to rural living, travel away from home, and co-infections with sexually 
transmitted diseases [89]. 
By the mid 1990’s, the  incidence of AIDS-KS in HIV positive individuals 
decreased significantly due to the introduction of highly active antiretroviral therapy 
(HAART)  [90, 91].  HAART represents the use of a combination of antiretroviral 
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pharmaceutical therapies, sometimes termed a drug cocktail.  It combines protease 
inhibitors with reverse transcriptase inhibitors, which helps to prevent the emergence of 
drug-resistant HIV strains and decrease viral load.  The success of HAART results in 
increased T-lymphocyte survival, decreased patient mortality rates, and a reduction in 
AIDS defining diseases such as KS.  In a study done on 14,183 people diagnosed with 
AIDS during 1990-2000 in San Francisco, CA, factors associated with a longer KS 
survival time included HAART use for 6 or more months (HR=0.37, 95% CI 0.31-0.45) 
[92].   
Transmission of HHV8 
Transmission of HHV-8 in adults has been suggested to occur via blood, bodily 
fluids, and sexual contact.  In industrialized countries, sexual transmission is highest in 
the population of men who have sex with men (MSM).  A study conducted on a San 
Francisco cohort of MSM, HHV-8 found significant rates of sexual transmission [93]. 
Engels et al (2007) in a study using the NHANES III cohort examined HHV-8 status on 
13,894 adults over 18 years of age for associated risk factors.  Their findings showed that 
among MSM seroprevalence increases with the number of previous male partners, and an 
association exists with HHV-8 seropositivity and duration of heterosexual activity and 
lifetime number of heterosexual partners.  However, no associations with sexual risk 
factors were found among women [94].  In contrast, a cohort in Zimbabwe of 
heterosexual men found that HHV-8 infection was not associated with any sexual risk 
factors other than with HIV-1 infection [95].  Taken together, these studies suggest that 
sexual transmission may occur, but is more likely to occur in MSM rather than 
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heterosexual sexual contact.  Sexual transmission does not explain the high prevalence of 
HHV-8 in endemic populations, and does not explain the risk of transmission to children. 
Blood and blood products have been explored as a potential route of transmission. 
Occurrence of HHV-8 transmission in intravenous drug users gives evidence that 
transmission via blood is possible [96-98].  Disparity among several studies suggests that 
transmission of HHV-8 via transfusion of blood or blood products is possible, but 
unlikely [99-101].  The reports of transmission via blood transfusion products vary 
greatly with geographical area.  Incidence rates are low in North America, and higher in 
areas of endemic HHV-8.  A Ugandan study demonstrated that 41 of 991 blood 
transfusion recipients seroconverted to be HHV-8 positive post transfusion, with an 
increase in risk noted in those receiving HHV-8 seropositive blood [102].  It is likely that 
the risk varies not only with population prevalence, but also with the differences in 
collection and storage of blood products. Such studies are difficult to conduct due to the 
co-morbidities of transfusion recipients that may bias results, as well as the anonymous 
nature of the blood donation, making it difficult to follow-up to confirm serodiagnostic 
tests. 
In children, there is a paucity of data regarding when and how transmission 
occurs.  HHV-8 has been shown to productively infect placental cells in vitro, confirming 
the possibility of mother to child vertical transmission [103].  In addition, epidemiologic 
studies have shown HHV-8 transmission from mother to child vertically during 
pregnancy, but the incidence is found to be low [104, 105]. The increase in the 
prevalence of HHV-8 throughout early childhood prior to onset of sexual activity 
suggests the possibility of additional routes of transmission via mother to child routes, 
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most likely during early childhood [106-108], or between household contacts and among 
children, possibly via saliva [109-111].  Another source to consider is breast milk.  
Although breast milk is known to transmit other viruses such as CMV and HIV-1, 
previous research indicates a lack of HHV-8 DNA in breast milk, making transmission 
unlikely [112]. 
Saliva has also been implicated in the transmission of other human herpesvirus 
family members, including HSV-1, HHV-6, and HHV-7 [113-115].  Our lab has 
previously isolated, HHV-8 virus in saliva samples from seropositive mothers implicating 
saliva as a likely mode of HHV-8 transmission [116].  Other published studies have also 
indicated saliva as a mode of transmission.  A South African study found that an 
increased prevalence of HHV-8 specific antibodies in children in mothers shedding >5 X 
104 viral DNA copies/ml of saliva, which suggests that l high viral load in saliva may be 
associated with transmission to the child [106].    
In examining HIV status as a risk factor for transmission of HHV-8, Miller et al. 
demonstrated that HIV-positive individuals were significantly more likely to shed HHV-8 
in their saliva than the uninfected controls (OR, 4.15 [95% CI, 1.87 to 9.19]) [117].  In 
the United States, saliva has been implicated as a source for transmission of HHV-8 in 
HIV positive individuals, because viral DNA has been detected in as many as 70% of oral 
cavity samples in studies involving HIV-1 infected men with KS [118].  However, our 
lab found no significant difference in HHV-8 viral shedding in saliva cells when 
comparing HIV-1 infected mothers and uninfected mothers in a mother/infant cohort 
from Lusaka Zambia [112].  HHV-8 infection in children was not found to be associated 
with either HHV-8 or HIV-1 infection of the mother [119], however we found while 
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following the same cohort longitudinally, that childhood HIV-1 status was a significant 
risk factor for the child to acquire HHV-8 infection by 48 months of age (HR, 4.60 
[95%CI, 2.93,7.22]) [120]. 
An interesting area of study in the epidemiology of infectious diseases is genetic 
risk.  A study in Sardinia identified an HLA predisposition in classic KS patients, 
identifying a positive association with types HLA-DRB1*1104, DRB1*1302, 
DQB1*0302, Cw7, and DQB1*0604 and a negative association with types A30, B58, 
Cw5, DRB1*1601, and DQB1*0502 [121].  A positive association was identified with 
AIDS-KS and a critical amino acid residue at position 13 in HLA-DRB1 [122].  These 
studies taken together with HHV-8 association with KS, has prompted studies into the 
genetic influence on HHV-8.  In a South African study, Alkharsah et al. (2007) found a 
significant association with allele groups HLA-1*68, HLA-1*43, and HLA-DRB1*04 
with an increased rate of viral shedding or increased viral load in a cohort of HHV-8 
infected mothers [123].  However, a Ugandan group did not find any associations with 
types HLA-A and HLA-DRB1 alleles, and only with children with the HLA-B allele.  
They found  a marginal association of KSHV DNA shedding in saliva but not in 
peripheral blood among children carrying HLA- B*4415 and marginal association of 
KSHV DNA shedding in peripheral blood but not in saliva among children carrying 
HLA- B*0801 alleles. This suggests that different populations could pose different 
genetic risks, however small sample size could bias their data [124].  Further longitudinal 
studies are needed to confirm the influence of haplotypes in increased risk of HHV-8 in 
populations and the subsequent transmission to susceptible children.    
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Whitby et al. (2007) proposed that environmental cofactors present in KS 
endemic regions are responsible for reactivation of HHV-8 in infected subjects, leading 
to high viral loads, increased viral shedding, and an increased risk of transmission.  
Dubbed the “oncoweed” hypothesis, this study presents in vitro data demonstrating an 
increased expression of KSHV mRNAs upon exposure to extracts from African native 
plants.  Several of these plants are used in native populations in activities such as basket 
weaving or in traditional medicine [81].  This data suggests a possible role of 
environmental factors as an originator of epigenetic changes, leading to increased viral 
replication and an increased risk of transmission.  
HHV-8 Diagnostics 
Polymerase chain reaction (PCR)-based methodology of HHV-8 DNA detection 
gives the greatest specificity for diagnosis, compared to all other tests currently used for 
measuring HHV-8 exposure or infection. Viral genomic copy number varies according to 
cell type and disease status. For example, chemically infected B lymphoma cells carry 
40-150 copies of HHV-8 DNA per cell genome, compared to 1-2 copies per cell in KS 
tissue. In terms of other body locations, viral DNA is most often found in saliva followed 
by peripheral blood mononuclear cells (PBMC) and occasionally in semen and the male 
urogenital tract. 
In PEL cells, also referred to as body cavity-based lymphoma cells (BCBL), 
HHV-8 DNA is detected at 100% efficiency, which corresponds to 100% assay 
sensitivity. In comparison, PCR of KS lesions from known HHV-8 positive patients is 
detected in approximately 95% of all cases. This discrepancy between BCBLs and KS 
tissues is believed to reflect the viral copy number as well as cellular heterogeneity of the 
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tissue opposed to the relative homogeneity of the single B-cell typed lymphoma. In 
circulating PBMCs and in the plasma, detection of HHV-8 DNA in seropositive 
individuals is very rare, possibly because of low levels of viral replication during latent 
infection. Viral DNA detection has been used to analyze HHV-8 disease-associated 
progression. Reactivation of latent virus and proliferative infection leads to an increase in 
viral load in the peripheral blood stream. This increased viral load contributes to 
increased viral dissemination and spreading of the infection. In KS patients, an increase 
in plasma viral DNA, isolated from other blood products including not lysed cells, has 
been used as an indicator of a more advanced viral infection. Studies have also 
demonstrated a strong correlation between viral load within the peripheral blood, 
including cells, and an increased risk of KS progression. Hence, peripheral blood viral 
load is used to predict the pathogenic outcome of the infection by measuring active HHV-
8 replication through PCR detection of viral DNA.  
The low sensitivity and expense of the method limit the clinical application of 
viral DNA detection in population screening.  Immunologic assays are the most widely 
used in HHV-8 diagnostics.  Currently four antibody detection assays are commonly used 
in HHV-8 serodiagnostics: enzyme-linked immunosorbant assay (ELISA), 
immunofluorescent assay (IFA), Western blot, and immunohistochemistry (IHC).    
Immunofluorescence assays (IFAs) are used extensively in serodiagnostics.  This 
technique employs a target cell expressing desired viral proteins fixed and spotted onto 
glass slides.  If antibodies specific for the expressed proteins are present in the patient’s 
plasma, those will attach to the antigen, indicating past or present patient exposure to the 
virus.  A detection antibody is then applied, usually a commercially available antispecies 
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(i.e. human) antibody with a fluorescent tag.  The slides can then be viewed with 
fluorescent microscopy to identify seropositive patients.  Target cells used in this assay  
are often B-cell lymphoma based cells, stimulated to express lytic phase proteins using 
either sodium butyrate [125], or12-O- tetradecanoylphorbol-13- acetate [126]. Antibodies 
recognizing lytic proteins will result in a whole cell fluorescent staining, whereas 
recognitions of latent proteins results in a more restricted, punctate nuclear appearance, 
demonstrating recognition of the latently expressed protein, LANA.  
 Also commonly used in IFAs are recombinant proteins expressed in insect cells.  
As discussed in later in chapter 5, Spodoptera frugiperda (Sf9) are cells that can be used 
for recombinant protein production using baculovirus expressing immunogenic proteins 
such as K8.1, LANA, and ORF65 [126]. 
HHV-8 in Zambia 
 In sub-Saharan Africa there has been an increase in KS co-incidental with the 
HIV epidemic and high incidence of HHV-8 infection, with seroprevalence reported to 
range from 20-48% [127, 128].   KS is known to be the most common tumor among HIV 
positive individuals [129]. 
A dramatic increase in incidence of KS was observed after the HIV epidemic. In 
children, KS was relatively rare prior to 1980, but by 1990 to 1992, post the emergence 
of the HIV epidemic, the incidence in children raise to constitute 20-25% of all pediatric 
malignancies in Zambia [130]. In this same study, pediatric KS incidence noted at the 
University Teaching Hospital in Lusaka, Zambia increased from 3.2% to 19% in just one 
decade [130].   
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Preliminary data from our laboratory has determined HHV-8 seroprevalence rate 
of Zambian children at 12, 24, 36, and 48 months of age as 15%, 20%, 18%, and 22% 
respectively [120].  While in utero HHV-8 infection is possible, it cannot account for the 
high HHV-8 seropositivity in children during the first 12 months of age. These findings 
suggest that horizontal transmission is likely the predominant mode of virus transmission 
in our targeted study population. The overall goal of my dissertation research is to 
delineate possible routes and risk factors of HHV-8 transmission within a household to a 
susceptible child.  Although breastfeeding has been implicated in early transmission of 
other viral diseases such as HIV our previous research has demonstrated that HHV-8 
DNA cannot be readily detected in breast milk. However, HHV-8 virus can be isolated in 
saliva samples obtained from seropositive mothers in our above defined cohort, 
implicating saliva as a likely mode of HHV-8 transmission to children, but the maternal 
serostatus of HHV-8 is not a significant risk factor in transmission [112]. 
STUDY AIMS 
The hypothesis of this dissertation research is that children in Sub-Saharan Africa 
can be infected by HHV-8 in early childhood through saliva contact with household 
members.  This research plan was designed to test this hypothesis.  To test our 
hypothesis, three specific aims were pursued, they are: 
1. To determine risk factors associating with HHV-8 positive children as compared 
to negative children 
a. Evaluating questionnaires specific to eating, feeding, and social practices 
within households. 
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b. Identifying significant behaviors or factors specific to either HHV-8 
positive or negative household members. 
c. Identifying health status associations such as child nutritional status or 
other co-infections as risk factors for HHV-8 infection.  
d. Completing statistical analysis to look for significant difference. 
2. Following the child for seroconversion post-enrollment in the study.  
a. Evaluating the uninfected child every four months to determine incidence 
of HHV-8 seroconversion.  
3. Determining the risk factors associated with the household and the child during 
seroconversion. 
a. Assessing if HHV-8 positive households increase the risk of 
seroconversion of the index child 
b. Assessing lifestyle habits or behaviors that increase exposure to saliva, 
blood or bodily fluids through extensive questionnaires. 
c. Identifying potential factors that could be of interest 
B. Socioeconomic factors 
C. Demographic data 
D. Co-infections 
d. Completing statistical analysis to look for significant difference. 
In chapter 2, The Zambia Children’s KS-HHV-8 Study is described in detail.  The 
study design, recruitment, enrollment and cohort description is presented.  Potentials for 
bias are addressed, and the socio-demographics of the enrolled cohort are described. 
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In chapter 3, specific aim 1 is met.  A baseline cross-sectional analysis is 
performed, examining 75 HHV-8 positive children that were enrolled into the study. 
Caregiver and household behaviors, health practices and child health status were 
analyzed.  HHV-8 presences in the household as well as behaviors such as testing the 
temperature of food prior to feeding to a child were determined to be significant risks of 
HHV-8 seropositivity. 
In chapter 4, specific aims 2 and 3 are met.  The children enrolled in the Zambia 
Children’s KS-HHV-8 Study are followed for the duration of 48 months.  Incidence rates 
are calculated, and risk analysis is completed. This prospective cohort study supports the 
findings of the first study in significant risks associated with saliva sharing behaviors and 
childhood acquisition of HHV-8. 
Also included in this dissertation in chapter 5 is a study that was completed in 
analytical methods. To complete the serodiagnostics of the children and household 
members, a reliable assay is required.  No gold standard exists for testing for HHV-8 
infection.  This final chapter outlines the work that was done prior to the beginning of the 
Zambia Children’s KS-HHV-8 study, and helps to exemplify some of the work involved 
in assay development.  
Overall, this dissertation describes the development of an epidemiologic study to 
examine HHV-8 transmission within households, and the association of transmission of 
HHV-8 to a susceptible child with behaviors that expose a child to saliva. Taken together, 
they describe epidemiologic, diagnostic, and analytical methods used in the investigation 
of risks associated with early childhood HHV-8 acquisition. 
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TABLES 
Table 1.  Human Herpesvirus Subfamilies, Associated Diseases in Humans, Cellular 
Tropism and Means of Transmission Among Humans. 
 
 
 
 
Virus name Subfamily 
Major 
associated 
disease in 
humans 
Cellular 
tropism 
Means of 
Transmission 
Herpes simplex 
virus Type I 
(HSV-1) 
α 
Oral herpes-Cold 
sores 
Sensory Nerve 
Ganglia 
Oral routes, 
sexual 
Herpes simplex 
virus Type 2 
(HSV-2) 
α Genital herpes 
Sensory Nerve 
Ganglia 
 
Sexual 
transmission 
Varicella Zoster 
Virus (VZV) 
(HHV-3) 
α 
Chicken-pox, 
shingles 
Sensory Nerve 
Ganglia 
Respiratory and 
sexual  
Epstein Barr 
virus (EBV) 
(HHV-4) 
γ 
Burkitt’s 
lymphoma 
nasal pharyngeal 
carcinoma 
Infectious 
mononucleosis 
B lymphocytes  
epithelial cells 
Saliva, 
transfusions, 
tissue 
transplant, and 
congenital 
Cytomegalovirus 
(CMV) (HHV-5) 
β 
Congenital 
disease resulting 
in hearing loss 
CD4+ T 
lymphocytes 
Saliva, urine, 
breast milk 
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ABSTRACT 
The HIV epidemic in Zambia has led to a dramatic rise in the incidence of human 
herpesvirus 8 (HHV-8) -associated Kaposi’s sarcoma in both adults and children. But 
there is a paucity of knowledge about the routes of HHV-8 transmission to young 
children. The Zambia Children’s KS-HHV8 Study; a large prospective cohort study in 
Lusaka, Zambia was launched in 2004 to investigate the role of household members as a 
source of HHV-8 infection in young children and social behaviors that may modify the 
risk of HHV-8 acquisition. This cohort is distinct from other epidemiological studies 
designed to investigate HHV-8 incidence and transmission because it recruited and 
followed complete households in the urban Central African context. Between July 2004 
to March 2007, 1,600 households were screened and 368 households comprising 464 
children and 1,335 caregivers and household members were enrolled. Follow-up of this 
population has continued for 48 months post-recruitment, affording a unique opportunity 
to study horizontal transmission of HHV-8 and understand the routes and sources of 
transmission to young children in Zambia. We describe the study rationale, design, 
execution and characteristics of this cohort which provides critical data on the 
epidemiology and transmission of HHV-8 to young children in Zambia.  
  
46 
 
INTRODUCTION 
Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma-associated 
herpesvirus (KSHV), is the most recently described human herpesvirus [1]. With the 
emergence of the HIV epidemic, Kaposi’s sarcoma (KS) has become one of the most 
frequently diagnosed cancers in sub-Saharan Africa [2]. The seroprevalence of HHV-8 
varies greatly and is generally high in areas where classic or endemic form of KS is 
common [3]. One such country is Zambia, a part of the “KS belt” where endemic KS was 
prevalent and where significant increase in KS incidence in adults and children has 
coincided with the emergence of the HIV-1 epidemic [4-6]. By 1992, KS accounted for 
approximately 25% of all childhood cancers diagnosed in Lusaka, the capital of Zambia 
[7].  
Routes of HHV-8 transmission and factors associated with increased risk of 
HHV-8 acquisition have yet to be delineated. Based on results from our previous cohort 
study in Zambia conducted from 1998 to 2003, we were the first to report that; 1) HHV-8 
may be transmitted perinatally albeit rarely; 2) HHV-8 may be detected in saliva but not 
in breast milk, and; 3) early childhood infection with HHV-8 is common [8-10]. Taken 
together, these results suggest that the major mode of HHV-8 transmission to children is 
by person-to-person contact, likely via saliva. We have also reported that HHV-8 
infection in young children could occur independently of the HHV-8 serostatus of the 
mother, suggesting the possible role of other household members in transmitting infection 
[10]. Therefore it is critical to evaluate the role of household contacts in transmitting 
infection to young children especially in HHV-8 endemic areas like Zambia. To date, 
there has been no cohort study designed to recruit and follow entire households to 
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investigate HHV-8 transmission within households. Socioeconomic factors such as low 
parental education, using water from a communal source and low income have been 
implicated as risk factors associated with HHV-8 seroprevalence; these studies were 
cross-sectional in design and thus unable to associate specific risk factors with incident 
HHV-8 infection [11-13]. Therefore, the Zambia Children’s KS-HHV8 study was 
designed in which longitudinal 4 year follow-up of recruited households was undertaken 
with the specific objective of determining the rate and source of horizontal transmission 
of HHV-8 to young children. We aimed to investigate whether transmission of HHV-8 to 
young children could occur through casual, person-to-person contact within a household.  
Conducting prospective cohort studies are challenging endeavors, particularly in 
resource poor settings such as Zambia, which has poor infrastructure, high poverty levels, 
and limited number of skilled personnel. The aim of this report is to describe the 
rationale, design, execution, logistics and characteristics of a large observational 
household-based cohort study in Lusaka, Zambia.  
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MATERIALS AND METHODS 
Study population and site 
The Zambia Children’s KS-HHV8 study is a community-based cohort study 
executed by investigators of the University of Zambia Teaching Hospital (UTH) in 
Lusaka, Zambia in collaboration with investigators at University of Nebraska Lincoln. 
The study coordinating office was based at the UTH, with an independent clinic for 
recruitment and follow-up of study participants and a fully equipped laboratory for 
biospecimen processing, testing, and storage. The study office also houses the data 
management team and the study coordinator; together they manage the paper and 
electronic versions of questionnaires, study- related forms and laboratory results. All 
study personnel at the clinic and laboratory are Zambians and all study related 
discussions and decisions are made by consensus by the study coordinator, Zambian and 
U.S.-based study directors and the principal investigators. This study was approved by 
the Institutional Review Board at the University of Nebraska-Lincoln and the Ethics 
Board of The University of Zambia. 
Screening for enrollment 
Recruitment and long-term follow-up of participants in Zambia can be a difficult 
process. There is general disinterest concerning participation in research studies as the 
economic and educational status of an average household is low, with approximately 
64% of Zambian households living below poverty (in 2006) [14]. Zambia is one of the 
poorest countries in sub-Saharan Africa with a large percentage of a highly mobile 
population living in unorganized and densely populated settlements called ‘compounds’, 
making it difficult to locate and track study participants. To achieve a high follow-up 
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rate, we tried a novel method to create interest in the study and encourage follow-up 
visits. Community health workers (CHW), who were trained and educated about the 
study goals, spread the information about the goals of the study in their community. 
CHWs were residents of Lusaka and were instructed to reach potential study participants 
not only from within their residential areas and clinics but also from areas and clinics in 
other compounds. CHWs provided potential study participants with the basic information 
about the study goals and expectations, and gave opportunity to ask questions. If 
interested, they were directed to visit the study office at UTH, where trained study nurses 
provided comprehensive information about the study and answered all relevant questions. 
HIV and HHV-8 counseling was also given and written informed consent was obtained to 
participate in the study. Upon obtaining consent, each household and each member of the 
household was given a unique identification number. Participation incentives included 
the availability of basic health care at the study clinic, counseling to all study participants, 
common medications at no cost and reimbursement of the travel cost to the study office 
and clinic.  
Our objective was to enroll complete households that had at least one HHV-8 
negative child (referred to as index child). The eligibility criteria were 1) having an 
HHV-8 negative index child between 6 and 24 months of age in a household (children 
younger than 24 months were screened for HHV-8 serostatus); 2) the household had to 
reside in Lusaka District. Our early research experience suggested that participants living 
outside Lusaka were difficult to recruit or follow-up because of their inability or 
disinterest in travelling to the study site at UTH. According to the 2000 census, 14% of 
the Zambian population lived in Lusaka District, we therefore decided to limit to study 
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participants residing in Lusaka District [15]; 3) all members of the household, up to a 
total of 10 members, had to agree to participate and visit the study office for scheduled 
follow-up visits. The size of the household was limited to 10 to help limit the number of 
possible contacts with the index child; 4) the child should not be seriously ill (for 
example, Tuberculosis, cancer, AIDS) on the day of screening to ensure timely follow-up 
visits. Seriously ill children were excluded only because of their inability to travel or 
health risks involved in travelling to the study clinic. On meeting all the eligibility 
criteria, all members of the household had to return to the study office for enrollment 
within one month of screening. In addition a small group (n=32) of HHV-8 positive 
children younger than 24 months of age were enrolled as a control group to investigate 
the risk factors for seroconversion for a baseline cross-sectional analysis.  
Enrollment and follow-up 
The HHV-8 negative children along with their primary caregiver were requested 
to return for follow-up visits every 4 months until age 48 months; the other household 
members were followed annually. During each visit, all the study participants received a 
physical exam and free medications for common ailments such as worm infestation, fever 
and minor aches and pains, and multivitamin supplements in case of malnourishment. 
During enrollment and at each follow up visit, various biologic specimens were collected 
as described in the next section, health assessments were completed, and questionnaires 
to obtain demographic and behavioral information were administered (Table 1). 
Throughout the duration of the study, increase in household size due to additions in the 
household were enrolled either as index children if under the age of two years, or as 
household members if older than two years. CHWs tracked study participants that did not 
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return for scheduled visits to remind them of their missed visits or, if they decided to 
withdraw, determine the withdrawal reasons. 
The major outcome variable of interest was HHV-8 serostatus at each visit. 
Outcome assessment was done by testing plasma collected from each infant during each 
follow up visit for evidence of HHV-8 infection as described previously [16]. HHV-8 
shedding in buccal cavity was also monitored at each visit. 
Data collection instruments and exposure assessment 
Structured interview questionnaires were developed to collect information on 
factors that may be associated with increased risk of horizontal transmission of HHV-8 to 
the index child. The content of these questionnaires were based on discussions with focus 
groups conducted in March 2004 [17]. Discussions with men and women from diverse 
ethnic and socioeconomic backgrounds were conducted to determine various behavioral 
and socio-cultural practices that could impact the risk of the index child acquiring HHV-
8. The questionnaires were administered to the caregiver during enrollment and at each 
follow-up visit in English or the local language (translated into commonly used 
languages, Bemba or Nyanja, by the interviewer). Questions pertained to household 
living conditions (electricity, water source, toilet facilities, number of rooms/sleeping 
areas, household density), behaviors involving food and drinks (premastication, sharing 
sweets and/or drinks), health and personal care practices (example, bathing habits, use of 
traditional medicine and the use of saliva to soothe injuries), demographic variables (sex, 
age, education of the primary caregiver, household size, playmates), medical history 
(ailments and hospitalizations) and health assessments of the primary caregiver and the 
child. Developmental milestones of the child were also recorded.  
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Data management 
Printed copies of the questionnaires and laboratory test results were recorded in 
the database and managed locally. Databases were generated by entering each form twice 
and comparing both entries to identify entry errors. At the initiation of the study we 
employed an optical character recognition software for transferring information from 
each form to the database. However, character recognition and record posting problems 
were frequently encountered leading to extensive manual data cleaning. Subsequently, 
manual entry using MS Access™ forms was employed leading to significant 
improvement in data quality. Copies of the database were regularly provided to the study 
staff at University of Nebraska-Lincoln where analytic datasets were generated and are 
currently being used for analysis, review and publication by study investigators.  
Biospecimen collection and processing 
All samples collected at the clinic were processed by the study laboratory within 
two hours of collection. Venous blood was collected from all the study participants at 
every visit and plasma was separated and stored. The peripheral blood mononuclear cell 
(PBMC) pellet was divided in two vials; one vial was stored at -80 ⁰C and the other vial 
was lysed for DNA extraction. During the screening visit, both the child and the caregiver 
were tested for presence of HHV-8 and HIV-1 antibodies as described previously [16]. 
Screening for the presence of HIV-1 antibodies was done using Abbott Determine 
(Abbott Laboratories, Chicago, USA) and confirmed using Unigold (Trinity Biotech, 
Ireland) test kits, according to Zambia Ministry of Health, HIV-1 testing guidelines. For 
children younger than 18 months of age, polymerase chain reaction (PCR) was performed 
in the study laboratory using dried blood spots. Buccal cells were also collected at each 
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visit by scraping the buccal cavity with a cotton swab, then stored in a collection tube 
containing cell lysis buffer until DNA was extracted. Buccal cell lysates were used for 
investigating HHV-8 shedding, frequency of shedding, and the viral load present in the 
oral cavity. 
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RESULTS 
From July 2004 to March 2007, caregivers from 1,600 Zambian households, 
including 1,657 index children younger than 24 months (referred to as index child) 
visited the study clinic for participation in the study. All were residents of one of 40 
townships within Lusaka District (Figure 1). While our attempt was to achieve sampling 
from all areas of the city, we were unable to sample equally from all residential areas 
especially areas with residents from higher socioeconomic status. Our goal was to recruit 
and retain at least 370 index children to have 85% power to detect HHV-8 seroconversion 
difference from 0.12 to 0.22 at a significance level of 0.05. By the end of the study period 
there were 464 index children and 1,335 household members enrolled (Figure 2). 
During the first visit to the clinic, eligibility was determined after the caregiver 
provided informed consent to participate in the study. Refusal to participate at this visit 
was rare (0.5%) because caregivers had a basic understanding about the study through 
CHWs before they attended the study clinic. The most common reason for refusal was 
fear of blood collection. Eligibility criteria were met by participants of 1,023 households 
who were invited to return with the entire household within one month (Figure 2). Of 
these, all members of 368 households (1,799 total study participants) were enrolled and 
followed. In 254 households, one or more household member(s) could not attend the 
study clinic within the specified enrollment period, were considered incomplete 
households and not followed at later time points. The enrollment rate of complete 
households per households initially screened was 23.0%. There was variation noted in 
enrollment rates between townships (P <0.0001), most likely as a result of distance and 
accessibility to the study site (data not shown).  
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The annual enrollment and characteristics of 464 index children and 1,335 
household members during the enrollment period are summarized in Table 2. Of the 464 
index children initially enrolled, 395 children (85%) returned for one or more visits. The 
baseline characteristics of the 368 enrolled complete households are summarized in Table 
3. Homes were generally small in size (mean - 2 rooms), with mean of 4.7 household 
members per household. A majority of the households were of lower socioeconomic 
status having no electricity, running water or in-home toilet.  
Table 4 summarizes the characteristics of the primary caregiver, and his/her 
relationship with the enrolled index child. There were a number of different household 
structures represented, including multiple index children in a single household. The 
second index child could be a younger sibling, a niece, nephew, or other extended family 
member living in the household. Of the 464 enrolled index children from 368 households, 
97% of caregivers were mothers to these children, while others included grandmothers, 
aunts, father and even cousins. A majority of primary caregivers were between 20-29 
years of age (54.3%, age range - 14 to 78). Households were classified as ‘two parent’ if 
both a mother and a father to at least one index child in the household were present, 
‘single parent’ if only one parent was available in the household (all the single parents in 
our enrolled cohort were mothers), and if there were no parents, or if the household 
included another adult such as an aunt or uncle, these households were classified as 
‘extended family’. Nearly half (48%) of the households were classified as either ‘single 
parent’, or ‘extended family’, which reflects a community continuing to suffer a high 
adult mortality rate from HIV/AIDS and related conditions. Most of the primary 
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caregivers in the cohort (54%) had completed primary education; no primary caregiver 
reported education beyond high school. 
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DISCUSSION 
In this report we describe the study rationale, design, and methods of the Zambia 
Children’s KS-HHV8 study in Lusaka, Zambia. This study is the only known study that 
has recruited and followed complete households, in an HIV/AIDS and KS endemic area 
like Zambia. Our objective was to design and implement a study to examine HHV-8 
incidence and factors associated with HHV-8 acquisition by young children. Collection 
of a wide range of demographic, medical and behavioral data and biological samples 
during each visit have enabled us to meet our objectives. 
Several steps implemented in this study ensured its success in recruitment and 
follow-up. This is a second cohort study being undertaken by our group. The present 
study allowed us to establish a fully equipped, modern diagnostic laboratory within the 
premises of UTH which provided no-cost service to UTH patients, helping build positive 
relationships with local health officials. Additionally, the establishment of the study 
clinic helped to provide basic medical care to study participants who seldom have access 
to quality medical care, encouraging participation and high follow-up rates. The study 
emphasized the follow-up of children for childhood health and wellness, prevention, of 
common childhood illnesses, with regular household checkups having a focus on the 
well-being of the child, rather than only emphasizing the testing for HIV-1 infection. This 
was done to increase participation rates because some households are not eager to 
participate in HIV-1 studies as compared to studies emphasizing the general well-being 
of the child. Close collaboration with local CHWs was of immense help during screening 
and recruitment of households as education level is low in most communities in Lusaka, 
which made it difficult to spread the correct message regarding the objectives of the 
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study. CHWs helped to educate the clients about the study objectives, and addressed 
participant fears and questions in the local language and familiar setting, achieving high 
consent rates among the participants who attended the study clinic. CHWs also reduced 
the need for lengthy study descriptions at the clinic as these had previously been 
provided, allowing for more time dedicated to medical or counseling needs. Also, all 
study personnel in Zambia were local people who helped in establishment of contacts and 
gaining the trust of study participants. This was critical in achieving enrollment goals and 
high follow-up rates. In our experience, research studies in Zambia will greatly benefit by 
clearly defining and explaining the benefits to study participants. High poverty level 
makes it difficult to garner interest about research studies in these participants because 
their individual problems are so severe that they have little time, energy or resources for 
participating in research studies.  
Cohort studies are a challenge to plan and execute, even more so in a low-
resource setting such as Zambia. In our experience, high-tech equipment does not work 
well without constant technical support. We believe that one of the reasons behind 
malfunctioning of the scanning software was the lack of firewall protection to the UTH 
network of computers. Affordable internet in Zambia is often slow and unreliable making 
many tasks tedious. Also, another common problem faced by the study personnel was 
ensuring that the enrolled household was indeed one unit. To establish this, all 
relationships were asked to be clearly defined by the client. For example, a client 
describing her sister’s son as “like a son” was further queried to understand if the client 
was taking care of the child briefly or that the child was indeed living with the household. 
The household structure in Zambia is markedly different from Western countries with a 
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common joint family system, leading to large household size. Addition of new household 
members is also common because of relatives staying for extended periods of time, as is 
the caring for young children whose one or both parents have died. Careful planning and 
explanation of definition of household is essential for such studies.  
This study design had several strengths. Most epidemiological studies on HHV-8 
reported to-date are cross-sectional in design and cannot provide incidence estimates 
during early childhood in relation to the factors that may be associated with increased 
incidence. Also, very few studies have focused on studying infection within households 
especially in endemic areas like Zambia. Unlike Western countries, where primary 
infection mostly occurs after adolescence, our previous studies have shown that children 
are infected in Zambia at a young age [10]. We have a unique opportunity to study 
whether the source of infection is from within or outside the household. But despite 
careful planning, this cohort may still have certain limitations. We were unable to recruit 
households from more affluent backgrounds, thus limiting the ability to generalize our 
findings to different living situations. However, with 64% of Zambian households living 
in poverty, our results will be generalizable to the majority of Zambian population. Also, 
since we had to limit the household size to 10, we may have missed the effect of larger 
household size on HHV-8 acquisition. Another potential limitation could be self-selection 
bias; because of provision of medical benefits, the participants in the study may have 
been of poorer overall health due to HHV-8 or HIV infection, and had more of an 
incentive to be enrolled as well as to continue follow-up. If a selection bias was present, 
we will still be able to assess HHV-8 acquisition, using information about overall health 
of individuals as predictor variables. Another limitation could be informational bias; 
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some of the questions regarding eating habits or personal care habits may incite a 
defensive response in the caregiver, resulting in answers that err towards more socially 
acceptable habits. To decrease this potential bias, the questionnaire was carefully worded 
to avoid possible negative connotation, and the nurses were instructed to ask questions in 
a non-judgmental manner. In addition, since participants were informed of their and their 
child’s HHV-8 status at follow-up visits, this could potentially alter their interactions 
with the child. The caregiver could assume that certain behaviors that were being asked 
on a regular basis were important and may change their behavior. To avoid this, 
participants were not instructed that any questioned behaviors were known to be 
associated with HHV-8 transmission.  
The results from this study have the potential to contribute towards the design of 
effective health behavior interventions for prevention of HHV-8 infection and overall 
community health promotion. Designing effective behavioral interventions to prevent 
HHV-8 transmission to young children requires us to investigate the degree to which that 
behavior is influenced by attitudes, perceived norms, and self-efficacy. The questionnaire 
data collected from study participants will be critical in understanding these potential 
determinants of transmission. The laboratory and virological data will help in 
understanding the biology of HHV-8 in the Zambian setting. To summarize, this study 
was designed to yield critical clinical, demographic, laboratory and behavioral data useful 
for answering a variety of questions about HHV-8 transmission, including: Does a child 
acquire HHV-8 infection from within a household? Does HIV-1 infection of the child or 
household member increase risk of HHV-8 acquisition in a child? What behavioral or life 
style risk factors increase the risk of acquiring HHV-8 by a child? 
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TABLES AND FIGURES 
FIGURE 1.  
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FIGURE 1. Outline Map of Zambia Depicting the Nine Provinces. City of Lusaka, the 
capital of Zambia, is a part of Lusaka district (shaded black). Lusaka District is a part of 
Lusaka province (shaded gray). Detailed Area Map of District of Lusaka, Zambia 
Showing the Distribution of Townships of the Households (N=1600) that were Screened 
for Enrollment in the Zambia Children’s KS-HHV8 study, 2004-2009. No. – Number, 
UTH – University Teaching Hospital 
 
Note:  
Number of households (n) enrolled from each township is indicated. Symbols represent 
the percentage of households enrolled from each township; filled squares- ≥10%, filled 
circles- 5-9.9%, open squares- 1-4.9%, open circles- <1%. 
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FIGURE 2.  
 
 
 
FIGURE 2. Flow Chart Describing the Recruitment of the Study Cohort for The Zambia 
Children’s KS-HHV8 Study, Lusaka, Zambia, 2004-2009. 
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TABLE 1. Questionnaires, Biological Specimens Collected and Laboratory Measures for the Zambia Children’s KS-HHV8 Study, 
Lusaka, Zambia, 2004-2009. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Visit Questionnaire Samples collected Tests performed 
Screening 
Screening questionnaire for 
eligibility Blood HHV-8 
Enrollment Enrollment questionnaire for: Blood, buccal swab HIV, CD4 count,  
 - basic medical examination  
HHV-8 serology, DNA shedding in buccal 
swabs 
 - demographic characteristics  Others, if indicated (Malaria, Syphillis) 
 - baseline data   
 
- household behavioral data 
-developmental milestones   
Follow-up Follow-up questionnaire Blood, buccal swab HIV, CD4 count,  
 - basic medical examination  
HHV-8 serology, DNA shedding in buccal 
swabs 
 - changes in medical conditions  Others, if indicated (Malaria, Syphillis) 
  
- household behavioral data 
-developmental milestones 
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TABLE 2. Enrollment Characteristics of study Participants During Each Year of the Zambia Children’s KS-HHV8 study, Lusaka, 
Zambia, 2004-2009. 
 Year 2004 Year 2005 Year 2006 Year 2007 Year 2008 Total 
 Number (%) Number (%) Number (%) Number (%) Number (%) Number (%) 
Index Children n=11 n=171 n=151 n=92 n=39 n=464 
Sex       
Female 6 (54.5) 81 (47.4) 62 (41.1) 46 (50.0) 24 (61.5) 219 (47.2) 
Male 5 (45.5) 90 (52.6) 89 (58.9) 46 (50.0) 15 (38.5) 245 (52.8) 
Age, months       
0 - 5 0 0 9 15 2 26 
6-12 4 61 64 45 33 207 
13-18 6 42 36 19 4 107 
19-24 1 51 41 10 0 103 
25-29 0 17 1 3 0 21 
Household Members n=38 n=567 n=500 n=226 n=4 n=1335 
Sex       
Female 19 (50.0) 321 (56.6) 288 (57.6) 136 (60.2) 2 (50.0) 766 (57.4) 
Male 19 (50.0) 246 (43.4) 212 (42.4) 90 (39.8) 2 (50.0) 569 (42.6) 
Age, years       
≤ 5, Child 9 104 89 39 0 241 
6-15, Youth 9 197 171 70 2 449 
> 15, Adult 20 266 240 117 2 645 
Total Enrolled 49 738 651 318 43 1799 
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TABLE 3. Characteristics of 368 Enrolled Households in the Zambia Children’s KS-
HHV8 study, Lusaka, Zambia, 2004-2009. 
 
Characteristic N (%) 
Number of Household members                       
≤3 87 (23.6) 
4-5 175 (47.6) 
>5 106 (28.8) 
Number of rooms in home                                                
1 89 (24.2) 
2-3 223 (60.6) 
≥4 23 (6.3) 
Electricity in home  
Yes 64 (17.4) 
No 270 (73.4) 
Toilet in home  
Shared outhouse (latrine) 329 (89.4) 
Flush toilet in own house 6 (1.6) 
Water source  
Community tap or shared with neighbors 291 (79.1) 
Tap outside on property or in own house 44 (12.0) 
 
Note:  All numbers do not equal total household numbers due to missing values  
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TABLE 4.  Characteristics of Primary Caregiver in the Zambia Children’s KS-HHV8 
study conducted in Lusaka, Zambia, 2004-2009. 
 
Characteristic N (%) 
Primary caregiver relationship to index child (N=464)   
Mother 449 (96.8) 
Grandmother 6 (1.3) 
Aunt 7 (1.5) 
Father 1 (0.2) 
Cousin 1 (0.2) 
Primary caregiver age (years) (N=368)            
<20 25 (6.8) 
20-29 200 (54.3) 
30-39 120 (32.6) 
≥40 23 (6.3) 
Parental caregiver status within households (N=368)   
Households with two parents 185 (50.3) 
Households with single parent 130(35.3) 
Households with extended family 53 (14.4) 
Education of the primary caregiver† (N=368)   
None 33 (9.0) 
Primary 200 (54.3) 
Secondary 102 (27.7) 
 
Note:  All numbers do not equal total household numbers due to missing values  
† A Primary caregiver is defined as the household member with the most contact with the 
child. 
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ABSTRACT  
Background: Human herpesvirus-8 (HHV-8) infection in early childhood is common 
throughout sub-Saharan Africa with prevalence increasing throughout childhood. 
Specific routes of transmission have not been clearly delineated, though HHV-8 is 
present in high concentrations in saliva.  
Methods: To understand the horizontal transmission of HHV-8 within households to 
children we enrolled for cross-sectional analysis; 251 households including 254 children, 
age two and under, in Lusaka, Zambia. For all children, plasma was screened for HHV-8 
and HIV-1 and health and behavioral questionnaires were completed. Multi-level logistic 
regression analysis was conducted to assess independent factors for HHV-8 infection in 
children.  
Results: Risk factors for HHV-8 infection included increasing number of HHV-8 positive 
household members [OR 2.5 (95% CI: 1.9, 3.3) P < 0.01] and having a primary caregiver 
who tested the temperature of food with their tongue prior to feeding the child [OR 2.4 
(95% CI: 1.93, 3.30) P =0.01]. Breastfeeding was protective against infection with HHV-
8 for children [OR 0.3 (95% CI: 0.16, 0.72) P <0.01].  
Conclusions: These results demonstrate that exposure to HHV-8 in the household 
increases risk for early childhood infection with specific feeding behaviors likely playing 
a role in transmission.  
Impact: Interventions to protect children from infection should emphasize the possibility 
of infection through sharing of foods. 
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INTRODUCTION 
Human herpesvirus 8 (HHV-8) is the most recently discovered member of the 
gamma- herpesvirus family [1]. Also known as Kaposi’s sarcoma-associated herpesvirus 
(KSHV), it is known to be the causative agent of Kaposi’s sarcoma (KS), as well as other 
malignancies such as primary effusion lymphoma [2] and multicentric Castleman’s 
disease [3]. Seroprevalence of HHV-8 depicts uneven distribution worldwide but is 
generally high in areas where non-HIV associated forms of KS (classic or endemic 
forms) are common [4]. Results of epidemiological studies on HHV-8 seroprevalence in 
African adults vary from 29% to 48% based on region and population group [5-7]. In 
children, seroprevalence differs significantly with age and between different geographical 
regions, and the prevalence of infection increases consistently throughout childhood and 
adolescence in young children in some endemic areas of Africa such as Zambia [8].  
Prior to the onset of the HIV/AIDS epidemic in the mid 1980’s, KS was rare in 
children even in KS endemic areas such as sub-Saharan Africa [9-13]. During the 
HIV/AIDS epidemic, KS incidence rates in Africa increased dramatically in both adults 
and children [14]. In Zambia, pediatric KS incidence increased from 3.2% to 19.0% as a 
direct result of the HIV/AIDS epidemic [10], and by 1990 constituted 20-25% of all 
Zambian pediatric malignancies [12]. Given the high prevalence of HIV infection in the 
population, this may have been associated with either an increased risk of acquisition of 
HHV-8 infection or an increased risk of HHV-8 transmission to young children. Hence, 
there is a need for a better understanding of the frequency of HHV-8 transmission during 
early childhood. 
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 In both Western and developing countries, the risk for HHV-8 infection is likely 
associated with horizontal transmission through saliva however; in children there is a 
paucity of data regarding when and how transmission occurs and, in particular, which 
behavioral factors are associated with an increased risk of transmission. Several studies 
have shown that horizontal transmission occurs within families, most likely through 
saliva exchange [15-17]. Our laboratory has previously reported the isolation of HHV-8 
viral DNA in saliva samples from seropositive mothers in Zambia. Results from these 
studies strongly suggest that child rearing behaviors associated with saliva exposure 
could be a risk factor for increased HHV-8 transmission [18]. Results from a recent study 
conducted in rural Uganda lend credence to this theory when it reported a possible, albeit 
weak association between variables associated with saliva exposure such as sharing of 
food and/or sauce plates and increased risk for infection with HHV-8 [19]. 
Our earlier longitudinal cohort study demonstrated that children in Zambia 
acquire HHV-8 infection early in life, with up to 40% of children being infected by 48 
months of age [20]. These results provide compelling evidence that horizontal 
transmission of HHV-8 infection during early childhood is associated with the high 
incidence of infection in children. Therefore, we hypothesized that behaviors associated 
with saliva exchange, such as sharing food, would increase the risk for HHV-8 
seropositivity. To date, no large epidemiological study has been conducted in an endemic 
area such as Zambia to investigate horizontal transmission of HHV-8 infection from 
within a household to children. In the present analysis we evaluated behavioral risk 
factors associated with household saliva exposure to delineate risk factors for HHV-8 
infection in young children in Zambia.   
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MATERIALS AND METHODS 
Study design and population 
The present study is a part of a larger longitudinal cohort study recruited for the 
purpose of determining of risk factors for early childhood infection with HHV8 n 
Zambia. This is a collaborative study among investigators at the University of Nebraska-
Lincoln and the University Teaching Hospital (UTH) of University of Zambia School of 
Medicine in Lusaka, Zambia to study HHV-8 and HIV infections in Zambia. Details of 
the study design, rationale and recruitment process for this study have been previously 
described in detail [21]. In brief, participant recruitment was conducted from August of 
2004 to April of 2007 at the KS/HHV8 Study Clinic situated within UTH. Community 
workers were hired from eligible participants in our previous mother to child HHV-8 
cohort transmission study specifically to inform community members about the study and 
to help with the screening and enrollment process [21].  
Inclusion criteria for enrollment were as follows; families with a child less than 2 
years of age (the index child), a resident of Lusaka, all family members willing to 
participate in annual follow-up visits and the primary caregiver and index child should 
commit to 4-month follow-up visits. The primary caregiver was the family member self-
described as the individual with the most individual contact with and providing care for 
the index child. Of the enrolled children, 75 HHV-8 positive children chosen at random 
were also enrolled for the present analysis to understand the risk factors associated with 
HHV-8 prevalence in this cohort. These children were randomly selected if the caregiver 
expressed the willingness to participate. 
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Written consent was obtained from the study participants after describing the 
purpose of the study. Informed consent was obtained from all adult participants, and 
primary caregivers provided consent for children in the household. Study approval was 
granted by the Institutional Review Boards of the University of Zambia and the 
University of Nebraska and all suggestions and modifications were incorporated in the 
study protocols. 
Data collection and measures 
The primary caregiver in each household was interviewed by trained study nurses 
using structured questionnaires that included questions on socio-demographic variables 
(gender, age, education of the primary caregiver, household size, number of playmates), 
household living conditions (electricity, water source, toilet type, number of 
rooms/sleeping areas, household density), behaviors involving food and drink 
(premastication of food , sharing sweets and/or drinks), and healthcare and personal care 
practices (bathing habits, use of traditional medicine, and use of saliva to clean children’s 
faces , soothe injuries or insect bites). The questionnaires were written, designed and 
initially tested on focus groups in 2004 before study enrollment was initiated [22]. 
Laboratory testing 
Sample collection. Blood samples were collected by venipuncture from all members of 
the household within eight months (mean 2.3 months) of each other. Family size is often 
large in Zambian households and everyone in the family is often unable to attend the 
clinic at the same time. HIV-1 testing was performed at the UTH clinic in Lusaka, 
Zambia and PBMC’s were isolated for PCR analysis for HIV-1 positive individuals. 
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Plasma samples were shipped to University of Nebraska-Lincoln, Nebraska for HHV-8 
serological analysis.  
HIV-1 Serology. Plasma was screened for HIV-1 antibodies using both Capillus 
(Cambridge Biotech), and Determine (Abbott Laboratories) according to the 
manufacturer’s instructions. A result was considered positive if one or both of these rapid 
screening assays revealed a positive result. For children under 18 months of age, early 
infant diagnosis using dried blood spot (DBS) was conducted. If children under 18 
months of age were found to be seropositive but no confirmatory DBS data was 
available, serostatus was based on serology results that were obtained at subsequent 
follow-up visits (>18 months of age). If follow-up visits were not completed, the HIV-1 
result was considered indeterminant.  
HHV-8 Serology. HHV-8 serological testing was conducted using a monoclonal 
antibody-enhanced immunofluorescence assay (mIFA). Plasma samples were diluted 
1:40 in phosphate buffered saline, and screening was performed on BC-3 cells (an 
Epstein-Barr virus negative and HHV-8 positive cell line) (American Type Culture 
Collection, Manassas, Virginia). BC-3 cells were grown in RPMI media supplemented 
with 20% heat-inactivated fetal calf serum, and antibiotics (100 U/ml penicillin, 100 
µg/ml streptomycin). Cells were stimulated to promote HHV-8 lytic cycle with 20 ng/ml 
of tetradecanoyl phorbal ester acetate. At 48 hours post stimulation, cells were fixed 
using 4% paraformaldehyde, permeablized using 0.1% Triton X-100, and then spotted on 
12-well teflon coated slides. The mIFA was performed with mouse monoclonal anti-
human IgG antibody (CRL 1786) (American Type Culture Collection, Manassas, 
Virginia) as secondary antibody, and DyLight 488-conjugated donkey anti-mouse IgG 
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(Thermo Scientific) as tertiary antibody. A plasma sample was considered to be positive 
if two readers independently determined the sample to be positive on two independent 
mIFA tests. Positive samples were tested on BJAB cells (an Epstein-Barr virus negative 
and HHV-8 negative B cell line) which performed the role of negative controls to rule out 
any non-specific binding of antibodies to cells. 
Data analysis 
Dataset for the present analysis was built and statistical analysis was conducted 
using SAS (v9.2) (Cary, NC, USA). Logistic regression model with manual forward 
stepwise selection was conducted to explore the strength and significant association 
between HHV-8 seroprevalence (outcome) and a range of household behavioral habits 
(covariates). Associations between covariates and outcome were also evaluated to 
identify potential confounders. Odds ratios (ORs), 95% confidence intervals (CI) and P 
values were calculated to identify risk factors for HHV-8 infection in children under 2 
years of age. Variables with a P value <0.05 in univariable analysis were included in a 
multivariable logistic regression model utilizing a manual forward selection process, to 
control for possible confounders and identify independent associations. Anthropometric Z 
scores were calculated using the NUTSTAT anthropometric software package (Epi Info, 
version 3.2.2; Centers for Disease Control and Prevention). Three households had 
multiple index children in one household. To account for a clustering affect, the data was 
also analyzed utilizing GEE logit link type 3 analyses though we did not observe any 
influence of clustering on the final results. 
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RESULTS 
We screened index children under the age of 24 months from 1,600 households 
within the city of Lusaka, Zambia. Eligibility criteria were met by participants of 1,023 
households. Of these, 622 primary caregivers along with their index children returned for 
enrollment and 368 of these returned with the complete household. There were 117 
households that had incomplete data and record completion at enrollment, thus 
information from 251 households was available for analysis. Total enrollment in the 
study included 251 households with 254 index children, and 877 family members as 
outlined in Figure 1. Of the 254 index children enrolled, 75 (29.5%) were HHV-8 
positive. Table 1 summarizes the characteristics of the HHV8 positive and negative 
children, their household sizes, primary caregivers, and the HHV-8 status of the 
household members.  Comparison of behavioral habits related to the care of the index 
child that could be potential risk factors for HHV-8 transmission to children was 
conducted in the group of HHV-8 positive children as compared to HHV-8 negative 
children. On univariate analysis, we found significant associations between the HHV-8 
serostatus of the primary caregiver including mother and father, youth and children in the 
household and risk for HHV-8 infection in the index child (Table 2). Specifically, an 
increased risk for HHV-8 infection was associated with a child having a primary 
caregiver who was HHV-8 positive [OR = 2.5 (95% CI: 1.44, 4.32) P <0.01]. There was 
a slightly stronger association if the mother was HHV-8 positive as opposed to other 
caregivers [OR = 2.7 (95% CI: 1.48, 4.77) P <0.01]. However, an increased risk for 
HHV-8 prevalence was associated with having any HHV-8 positive adult household 
member [OR = 2.1 (95% CI: 1.11, 3.92) P = 0.03], and there was an increased odds of 
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1.8 [(95% CI: 1.22, 2.51) P <0.01], for every additional adult household member who 
was HHV-8 positive. The increasing total number of HHV-8 positive household 
members, including youth, was associated with an even higher odds of 2.5 (95% CI: 1.91, 
3.21) P <0.01. 
 We found no associations between child anthropometrics (weight and height 
percentiles), and risk for HHV-8 prevalence (Table 3). Additionally, there was no 
association between CD4 and CD8 cell count, hematocrit and hemoglobin levels and risk 
for HHV-8 prevalence in children (Table 3). The association between HHV-8 prevalence 
and socio-demographic variables was also examined, including age, gender, number of 
household members categorized by age, relationship of primary caregiver to index child, 
parental age, and primary caregiver education. There was an increased risk associated 
with having a greater number of adults in the household (Number of household members 
> 15 years of age) [OR = 1.5 (95% CI: 0.99, 2.18) P = 0.05] (Table 3), however we found 
no association between the other variables including child age, gender, adult age, 
education level and increased risk of infection. 
 We also examined for an association between HHV-8 seroprevalence in children 
and household and community specific living condition covariates including crowding, 
water source, toilet availability, number of rooms and sleeping areas in the home, 
crowding of persons in sleeping areas, number of playmates and number of playmates 
under the age of 5, and number of times weekly the index child spends overnight with 
friends. No associations were found with any of these covariates and child HHV-8 
serostatus (Table 4). Similarly, we found no association between HHV-8 seroprevalence 
in children and health and hygiene exposures including number of full-body baths, daily 
80 
 
face cleanings, use of traditional medicine, and use of saliva to clean child’s face, soothe 
childhood injuries, or insect bites (Table 4) although having a toilet within the household 
was marginally significant for protecting against HHV-8 infection [OR = 0.1 (95% CI: 
0.01, 1.34) P=0.09).  
We also investigated covariates related to feeding practices to investigate the 
association with HHV-8 seroprevalence and observed that there was decreased odds of 
HHV-8 seropositivity  when the children was currently being breastfed [OR = 0.5 (95% 
CI:  0.27, 0.88) P = 0.01] or if the child had ever been breastfed [OR = 0.4 (95% CI: 0.21, 
0.74) P <0.01] (Table 5). A number of feeding practices that involved exchange of saliva 
were evaluated to assess for association with HHV-8 prevalence including premastication 
and sharing of foods. Having a HHV-8 positive caregiver premasticate the food prior to 
feeding the child did not demonstrate significantly increased odds for HHV-8 prevalence, 
although a small number of caregivers indicated that this practice was performed limiting 
our overall sample size (data not shown).  
Upon multivariable logistic regression analysis, an independent association for 
HHV-8 prevalence included total number of HHV-8 positive household members [OR = 
2.5 (95% CI: 1.93, 3.30) P< 0.01] or having the primary caregiver taste the temperature 
of the food prior to feeding [OR = 2.4 (95% CI: 1.19, 4.73) P = 0.01] (Table 6). Current 
or past breastfeeding [OR = 0.3 (95% CI: 0.16, 0.72) P <0.01] was protective against 
infection with HHV-8. 
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DISCUSSION 
  In sub-Saharan Africa children become infected with HHV-8 at an early age.  
Our cohort studies have reported that by 13.4% of Zambian children were infected 12 
months of age [23].  An additional Ugandan study found comparable levels of infection 
by 2 years of age [24]. Zambia is a part of the “KS belt”, an area with endemic KS that 
has been severely impacted subsequently by the HIV epidemic, underscoring the need for 
epidemiologic studies to better understand patterns of HHV-8 transmission in young 
children. Although sexual transmission in adults and mucosal shedding of HHV-8 along 
with salivary exposure has been implicated in the transmission of HHV-8 in adults, there 
is little information about routes of transmission in children, and behavioral habits that 
could be potential risk factors and sources of transmission within the family.  
 Although other studies have examined childhood HHV-8 infection as a result of 
transmission between mother and child or between siblings [17, 25, 26], few have 
examined specific household behaviors that could contribute to virus transmission to a 
susceptible child within a household. The strengths of our study include utilization of a 
detailed questionnaire designed to assess behavioral habits not only engaged by the 
mother, but by household members and even the child’s interaction with neighborhood 
children. Ours is one of the first studies demonstrating an association between behavioral 
factors associated with saliva exchange, specifically feeding practices such as testing 
food prior to feeding, and infection with HHV-8 in early childhood. Butler et al. 
previously demonstrated a significant association with HHV-8 in children <14 years of 
age and sharing a sauce plate with other household members [19]. Our study did not 
demonstrate a significant association in any of our household food sharing variables in 
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the univariable analysis, most importantly, an absence of any association with 
premastication, however our sample size was small in contrast with other studies [19]. 
However, we did observe that in the multivariable analysis a specific behavior i.e. the 
primary caregiver testing temperature of food prior to feeding was associated with HHV-
8 prevalence, which potentially supports Butler et al’s association with food sharing 
behaviors [19]. 
 In the present study, we observed that presence and number of HHV-8 positive 
household members was consistently associated with childhood HHV-8 infection. This 
suggests person-to-person contact with HHV-8 positive members is likely to play a key 
role in transmission. These results have been further confirmed by a study completed in 
our lab utilizing molecular analysis of the K1 gene sequence data of KSHV-positive 
individuals from nine households in our cohort [27]. Olp et al found that in six of the nine 
households, the child had 100% sequence identify to all household members, supporting 
that intra-household transmission occurs [27]. 
 Our study tested multiple behavioral habits of caregivers and household members 
in which saliva exchange could occur with the child. We also investigated whether these 
behaviors were practiced by the primary caregiver, or if the primary caregiver observed 
other household members practicing the behavior to test the hypothesis that HHV-8 was 
spread through child-rearing behaviors associated with saliva exposure. We observed that 
both the primary caregiver’s and  the mother’s  HHV-8 status were the most significant 
factors, most likely due to more  frequent and close person-to-person contact. This 
contact likely occurs during food exchange behaviors, when possible saliva exchange 
occurs. But in this study, none of the child rearing behaviors individually were associated 
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with HHV-8 prevalence with the exception of the primary caregiver testing the 
temperature of the food before feeding the child. It is likely that for a HHV-8 
transmission event to occur the amount of saliva and the amount of viral shedding at the 
time of the behavior may be key factors. Seroreversion, the fluctuation in antibody titers 
to undetectable levels, in adults is well documented, and could correlate to viral shedding 
and likelihood of transmission. Also, the frequency of occurrence of each behavior over 
time could be critical but this was not fully explored in this study. It is also likely that the 
behavioral habits analyzed in this study such as sharing drinks and foods, involve 
exposure to only minimal amount of saliva. Similarly, Butler et al’s (2011) paper, 
reporting only a marginal association of sharing food and/or sauce plates with HHV-8 
infection in children could support the fact that the amount or frequency of saliva sharing 
could be a factor [19].  
Breastfeeding as a protection against HHV-8 infection is a novel finding among 
herpesviruses. Breast milk has been implicated in mother to child transmission of several 
viruses, including cytomegalovirus and HIV-1 [28, 29]. However, to our knowledge, this 
is the first report of breastfeeding as protection against childhood infection of HHV-8 or 
any herpesvirus. It is likely that there may be non-specific immune factors responsible for 
breast milk protection, including lactoferrin, complement components, or even 
commensal organisms. Overall, our finding of the decreased risk of HHV-8 infection 
associated with breastfeeding is intriguing and warrants further studies to identify the 
protective factors that may be responsible. 
HIV-1 infection has been documented to be a risk factor associated with HHV-8 
infection. However, we did not analyze the association of HIV-1 with HHV-8 infection in 
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the current study, because our subjects were selected to be HHV-8 negative as part of a 
larger longitudinal study with an aim to study HHV-8 incidence in early childhood. Our 
earlier cohort studies have clearly demonstrated that HIV infected children are at a 
significantly higher risk for acquiring HHV-8 infection [23]. Therefore, during the 
enrollment of this cohort, in which HHV-8 negative children were being recruited, it is 
likely that HIV-1 positive children were under-represented because they were already 
HHV-8 infected.  
A limitation of our study is that the behavioral questions were self-reported which 
could potentially result in recall bias. HIV-1 status of the household members was 
reported to the study subjects at study enrollment and counseling was done regarding 
transmission of HIV-1 and preventative health measures. However, since HHV-8 status 
was not known by the caregivers at the time of the study, we do not believe that this 
potential for bias was a significant factor. 
In summary, we have demonstrated that the presence of HHV-8 in the household 
plays a key role in transmission of the virus to a susceptible child. This likely occurs 
through saliva sharing during behaviors such as testing the temperature before sharing to 
the child. This finding has implications for public health risk, and the need for education 
of families of potential transmission of the virus when sharing food with young children, 
and needed behavior changes. Although the current analysis supports the view that the 
primary caregiver poses the most significant risk of transmitting HHV-8 infection to a 
child, other results from the same cohort also demonstrate that HHV-8 transmission to a 
child can also occur from other household members and even from others outside of the 
household [27]. Whether similar factors are also associated with HHV-8 incident 
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infection in “at-risk” children is the current focus of this study. Longitudinally followed 
children in this cohort up to 48 months after enrollment will improve our understanding 
of the nature of interpersonal contact with a child and its role in HHV-8 transmission. 
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TABLES AND FIGURES 
Table 1.  Demographics and HHV-8 Characteristics of HHV-8 Positive and HHV-8 
Negative Children in Lusaka, Zambia, 2004-2007. 
 
Characteristic 
HHV8 +               
(n=179) 
HHV8 -                     
(n=75) 
Demographics   
Age of index child (months):        
Range 4-25  2-28 
Mean 13.4  13.5  
Sex of index child:   
   Males 28 93 
Females 47 86 
Number of household members:   
Range 2-8 2-8 
Mean 4.7 4.5 
Number of  adults:   
Range 1-4 1-4 
Mean 1.8 1.7 
Age of primary caregiver (years):   
Range 17-49 14-58 
Mean 28.9 27.3 
Education of primary caregiver:   
None 7 18 
Primary school 47 105 
Secondary school  21 56 
Household HHV-8   
Primary caregiver HHV-8+ 52/75 (69.3%) 82/179 (45.8%) 
Mother HHV-8+ 51/72 (70.8%) 79/175 (45.1%) 
Father HHV-8+ 23/36 (63.9%) 44/74 (59.5%) 
≥ 1 other household member HHV-8+ 68/75 (90.7%) 143/179 (79.9%) 
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Table 2. Univariable Analysis to Investigate the Association of HHV-8 Serological Status of Household Members with Child HHV-8 
Seropositivity in Lusaka, Zambia, 2004-2007. 
 
Characteristic 
Odds 
Ratio 
95% Confidence 
interval 
P value 
Adult and Household HHV-8 Risk Factors    
≥ 1 household member HHV-8+ 2.7 1.23, 5.78 0.01a 
Increasing number of HHV-8+ household members 2.5 1.91, 3.21 <0.01a 
Primary caregiver HHV-8+ 2.5 1.44, 4.32 <0.01a 
Mother HHV-8+ 2.7 1.48, 4.77 <0.01a 
Father HHV-8+ 1.2 0.49, 2.67 0.66 
≥ 1 adult household member HHV-8+ 2.1 1.11, 3.92 0.03a 
Increasing number HHV-8+ adult household members  1.8 1.22, 2.51 <0.01a 
Youth HHV-8 Risk Factors    
≥ 1 household youth HHV-8+ 1.4 0.70, 2.84 0.30 
Increasing number of household youth HHV-8+ 1.3 0.90, 1.99 0.16 
Any other household child HHV8 + 1.3 0.66, 2.74 0.52 
 
a Significant at α level of 0.05  bTotal numbers vary reflecting family members enrolled in study 
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Table 3. Univariable Analysis to Investigate the Association of Socio-Demographic 
Factors and Nutritional and Immunological Factors with Child HHV-8 Seropositivity in 
Lusaka, Zambia, 2004-2007. 
 
a Significant at α level of 0.05
Characteristic 
Odds 
Ratio 
95% 
Confidence 
interval 
P value 
   Child specific characteristics    
Age of index child (months) 1.0 0.96, 1.04 0.99 
Gender of index child (Reference: male) 0.6 0.37, 1.19 0.12 
   Household specific characteristics    
Number of household members 1.1 0.94, 1.36 0.18 
Number of household adults  > 15 yrs 1.5 0.99, 2.18 0.05a 
Number of household youth (age > 5, ≤ 15yrs) 1.1 0.85, 1.37 0.51 
Number of household children (age ≤ 5 yrs) 1.0 0.68, 1.52 0.93 
Two parents vs. single parent household 1.6 0.86, 2.93 0.45 
Extended family parenting vs. single parent 
household 1.6 0.75, 3.58 0.45 
   Caregiver and adult specific characteristics    
Relationship of primary caregiver to index child:     
- Aunt vs. Mother 5.0 0.44, 56.0 0.99 
- Grandmother vs. Mother 0.7 0.27, 10.2 0.98 
Maternal age (years) 1.0 0.99, 1.08 0.13 
Paternal age (years) 1.0 0.98, 1.06 0.42 
Primary caregiver age (years) 1.0 0.99, 1.08 0.10 
Primary caregiver education:          
- No school vs. junior primary 1.5 0.48, 4.53 0.30 
- No school vs. upper primary 1.1 0.41, 2.79 0.93 
- No school vs. junior secondary 1.1 0.38, 3.19 0.87 
- No school vs. upper secondary 0.7 0.21, 2.59 0.37 
Nutritional status indicators    
Length-for-age or stature-for-age percentile 1.0 0.99, 1.01 0.70 
Weight-for-length or weight-for-stature percentile 1.0 0.99, 1.00 0.42 
Weight-for-age percentile 1.0 0.99, 1.00 0.13 
Laboratory values    
CD4 count 1.0 0.99, 1.00 0.27 
CD8 count 1.0 0.99, 1.00 0.18 
Hematocrit  1.1 0.86, 1.48 0.39 
Hematocrit (normal) 1.2 0.44, 3.11 0.76 
Hemoglobin 1.3 0.76, 2.30 0.33 
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Table 4. Univariable Analysis to Investigate the Association of Household and Personal Care Factors with Child HHV-8 
Seropositivity in Lusaka, Zambia, 2004-2007.  
 
Characteristic Odds Ratio 95% Confidence interval P value 
Household and Community Characteristics       
Water source (Community vs. within household) 0.9 0.41, 2.12 0.85 
Toilet location (Community vs. within household) 0.1 0.01, 1.34 0.09 
Number of rooms in the household 1.2 1.00, 1.54 0.12 
Number of sleeping areas in the household 1.4 0.94, 2.19 0.10 
Persons per sleeping area 1.0 0.79, 1.32 0.90 
Number of playmates 1.0 0.91, 1.23 0.99 
Number of playmates < age 5 1.0 0.84, 1.29 0.61 
  Hygiene practices    
Number of daily full-body baths for index child 1.2 0.59, 2.39 0.58 
Number of daily face cleanings for index child 1.1 0.51, 2.12 0.87 
Saliva used to clean child's face 1.1 0.42, 2.89 0.81 
Biting the child's nails to shorten them 0.6 0.34, 1.30 0.21 
Health practices    
Saliva used to soothe insect bites 1.3 0.41, 4.22 0.60 
Caregiver sucks mucus from child’s nose 1.7 0.56, 4.83 0.28 
Traditional teething remedies used 1.0 0.72, 1.48 0.88 
Use of Traditional Medicine 0.2 0.03, 1.60 0.13 
Lifebuoy soap for constipation 1.0 0.54, 2.26 0.92 
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Table 5. Univariable Analysis to Investigate the Association of Child Feeding Behavioral Habits of Household with Child HHV-8 
Seropositivity in Lusaka, Zambia, 2004-2007.  
 
Characteristic Odds Ratio 
95% 
Confidence 
interval 
P value 
 Breastfeeding practices    
Child has ever been breastfed  0.4 0.21, 0.74 <0.01a 
Child is currently being breastfed 0.5 0.27, 0.88 0.01a 
Primary caregiver moistens nipples with saliva prior to breastfeeding 1.0 0.38, 2.21 0.96 
   Premastication    
Adult premasticates food prior to sharing with children 1.2 0.60, 2.72 0.61 
Primary caregiver performs premastication 1.1 0.54, 2.47 0.86 
Other household members perform the premastication 1.8 0.51, 5.68 0.35 
 Adult feeding variables    
  Primary caregiver testing temp of food with tongue prior to sharing w/ 
child 
1.6 0.91, 2.89 0.09 
Blowing on food prior to sharing with child 1.1 0.67, 1.90 0.69 
Sucking on sweets prior to sharing with child 1.1 0.61, 1.89 0.80 
   Child and household food sharing variables    
Child shares sweets with other neighborhood children 0.9 0.44, 2.02 0.71 
Child shares sweets with other household members 1.1 0.64, 1.89 0.87 
Child shares drinks with other children 0.5 0.24, 1.37 0.19 
Household members share common utensils for meals 0.8 0.34, 1.88 0.58 
Household members share drinks with child 1.0 0.50, 1.84 0.89 
 
a Significant at α level of 0.05 
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Table 6. Multivariable Analysis to Investigate Independently Associated Risk Factors Associated with HHV-8 Seropositivity in 
Children in Lusaka, Zambia, 2004-2007. 
 
 
Characteristic 
Odds Ratio 95% Confidence interval P value 
Age of index child (in months) 1.0 0.94, 1.10 0.75 
Total number of HHV-8+ household members 2.5 1.93, 3.30 <0.01a 
Primary caregiver testing temperature of food prior to feeding 2.4 1.19, 4.73 0.01a 
Child breastfed currently or in the past 0.3 0.16, 0.72 <0.01a 
 
a Significant at α level of 0.05 
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FIGURE LEGEND 
Figure 1. Flow Chart outlining the screening and recruitment of study cohort in Lusaka, 
Zambia, 2004-2007. 
Figure 1. 
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CHAPTER 4:   CHILDHOOD FEEDING PRACTICES AS A RISK 
FOR CHILDHOOD HHV-8 ACQUISITION 
 
ABSTRACT  
Background: Human herpesvirus-8 (HHV-8) infection occurs at an early age in endemic 
areas such as sub-Saharan Africa. Although saliva is commonly implicated as the culprit 
in viral transmission to young children, specific behavioral practices as sources of 
transmission have not been clearly delineated.  
Methods: To further investigate specific characteristics and household behaviors that are 
associated with the risk of transmission of HHV-8 within households to children in 
Lusaka, Zambia, we enrolled and followed 270 children, age two and under. For all 
children, plasma was screened for HHV-8 and HIV-1 and health and behavioral 
questionnaires were completed. Multi-level Cox proportional hazard analysis was 
conducted to assess independent factors for HHV-8 infection in children.  
Results: Most significant independent risk factors for HHV-8 seroconversion included 
age at seroconversion (P < 0.0001), age at enrollment [HR 2.62 (95% CI: 1.64, 4.21) P < 
0.001],  child currently being breastfed [HR = 2.13 (95% CI:1.31, 3.44) P = 0.002], use 
of pacifier [HR = 9.00 (95% CI:1.65, 49.19) P = 0.01], child HIV-1 status [HR = 2.26 
(95% CI:1.19, 4.30) P = 0.013], and other individuals blowing on food prior to sharing 
with child [HR = 2.79 (95% CI:1.01, 7.76) P = 0.05].  
Conclusions: These results demonstrate behaviors in the household that potentially 
expose the young child to HHV-8 through exposure to saliva increases risk for early 
childhood infection.  
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INTRODUCTION 
Human Herpesvirus-8 (HHV-8) or Kaposi’s sarcoma associated herpesvirus 
(KSHV) is the eighth known human herpesvirus to be discovered.  HHV-8 is known to be 
associated with the development of Kaposi’s sarcoma (KS), primary effusion lymphoma, 
and multicentric Castleman disease.  Seroprevalence of HHV-8 varies according to 
geographic location.  In the United States and Western Europe, HHV-8 infection is 
uncommon in the general population, with higher prevalence in men who have sex with 
men (MSM) [1, 2]. In sub-Saharan Africa and Mediterranean regions, HHV-8 is 
considered to be endemic, however much is yet to be elucidated regarding HHV-8 risk 
factors and transmission.  Our lab has previously shown that Zambian children acquired 
HHV-8 infection early in life, with up to 40% of children becoming HHV8 positive by 48 
months of age [3].  Transmission via breastmilk is a possibility, as cytomegalovirus, 
another herpesvirus is transmissible via breastmilk, however HHV-8 DNA is not readily 
isolated from breast milk [4-6].  In HHV-8 seropositive mothers high viral titers of HHV-
8 is frequently isolated in saliva [5-7].  In a previous study from a South African 
population, children of mothers with high viral load (>50,000 copies/mL) in saliva, were 
nearly three times more likely to be HHV-8 positive, than if the mother did not shed 
HHV-8 in saliva [5].  Several studies have shown that transmission of HHV-8 occurs 
within households, most likely via saliva exchange [8-10].  Taken together, these findings 
implicate salivary transmission as the likely culprit for early childhood infection, 
however, the mode by which saliva exchange could occur is unclear.  A rural Ugandan 
study found food and/or sauce plate sharing within households as an associated risk for 
HHV-8 in children under age 14 [11].  These studies support our hypothesis that 
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behaviors within the household that expose children to saliva at an early age increase the 
risk of childhood acquisition of HHV-8.  To investigate horizontal transmission of HHV-
8 infection from within a household to children, we conducted an epidemiologic study in 
collaboration among investigators at the University of Nebraska-Lincoln and the 
University Teaching Hospital (UTH) of University of Zambia School of Medicine in 
Lusaka, Zambia.  In this present study, we report findings from a longitudinal cohort in 
order to assess childhood incidence rates of HHV-8 infection and the associated socio-
demographic, child feeding and rearing behaviors and health care practices that could be 
associated with acquisition of HHV-8 infection.    
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METHODS 
Study setting  
Details of the study design, rationale, and recruitment process for this study have been 
described in detail previously [12].  In brief, participants were recruited from August, 
2004, to April, 2007 at the study clinic in Lusaka, Zambia.  Community workers were 
hired to participate in informing community members about the study, recruitment of 
eligible study participants, and assist in maintaining follow-up with study participants 
[12]. 
Inclusion criteria for enrollment were; family with a child less than 2 years of age 
(the index child), family should be a resident of Lusaka, all family members should be 
willing to participate in annual follow-up visits and the primary caregiver and index child 
should commit to 4-month follow-up visits. The primary caregiver was the family 
member self-described as the individual with the most individual contact with and 
provided care for the index child.  Children and members of their households who meet 
study eligibility criteria, signed informed consent before enrolling into the study. Written 
informed consent was obtained from all adult participants, and primary caregivers 
provided consent for children in the household.   
Once study participants were enrolled, the primary caregiver and index children 
returned for follow-up visits every four to six months to reassess their serological status 
for HHV-8 and/or HIV, and to complete a risk assessment questionnaire for acquisition 
of HHV-8 infection. At each visit, a thorough physical examination was performed, new 
blood specimens and saliva specimen collected and tested for HHV-8 and HIV-1 
100 
 
infection. All family members were assessed at enrollment, with specimen collection and 
annually thereafter. 
As part of the study incentives, each participant was provided multivitamins and 
other medications when indicated and a chance for their infant to be followed-up by a 
reputable pediatrician. At all visits, all subjects were provided with counseling about risk 
reduction for HIV. Study approval was granted by the Institutional Review Boards of the 
University of Zambia and the University of Nebraska. 
Data collection and measures 
Questionnaires were designed as described in detail in chapter 2.  In brief, questionnaires 
specific for risk assessment were completed by primary caregivers and evaluated upon 
seroconversion of the child.  These questionnaires address potential sources of blood or 
body fluids from household members to the index child, with detailed questions 
surrounding incidents that could possibly account for salivary exposure.  Data collected 
included: socio-demographics (age, gender, occupation, place of residence, marital status, 
number-gender-age of children, number-gender-age of siblings); medical conditions 
(height, weight, blood pressure, immunization history, breastfeeding history including 
duration, frequency and type of any illness-related signs and symptoms, major disease 
history, current medication use); laboratory testing (HIV, HHV-8); household living 
conditions (number of people living in the house, number and type of rooms in the house, 
nature of the water supply, access to toilet, etc.); family structure (two, one or no parents, 
number and type of child’s caretakers: mother, extended family, siblings);  household 
life-style risk factors (sharing dental cleaning materials, sharing pacifiers, eating with 
fingers from a common bowl, sharing drinks); and child care giving behaviors (frequency 
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and type of feeding, bathing, face washing, etc.). The questionnaires were written and 
designed and initially tested on focus groups in 2004 before study enrollment was 
initiated [13]. 
Laboratory testing 
Sample collection. Blood samples were collected by venipuncture from all members of 
the household. Family size is often large in Zambian households and everyone in the 
family is often unable to attend the clinic at the same time. HIV-1 testing was performed 
at the UTH clinic in Lusaka, Zambia and PBMC’s were isolated for PCR analysis for 
HIV-1 positive individuals. Plasma samples were shipped to University of Nebraska-
Lincoln, Nebraska for HHV-8 serological analysis.  
HHV-8 Serology: Antibodies against HHV-8 latency-associated nuclear antigen (LANA) 
and HHV-8 lytic antigens was determined by immunofluorescence assays (IFAs), at a 
dilution of 1:40, using a primary effusion lymphoma (BC-3) cell line, negative for 
Epstein-Barr virus.   The viral lytic cycle was induced by incubating BC-3 cells with 20 
ng/mL 12-Otetradecanoylphorbol-13-acetate (TPA) (Sigma) for 48 hours.  Fixing of cells 
was completed with 4% paraformaldehyde and permeabilized using 0.1% Triton X-100.  
Post-fixing, the cells were spotted on 12-well Teflon coated slides and allowed to air dry.  
The mIFA signal was enhanced using a monoclonal mouse anti-human IgG antibody 
(CRL 1786, ATCC) [14] as the secondary antibody, and DyLightTM 488-conjugated 
donkey anti-mouse antibody (Jackson Immuno Research) as the tertiary and detection 
antibody.  A plasma sample was considered to be positive if two readers independently 
determined the sample to be positive on two independent mIFA tests. Positive samples 
were tested on BJAB cells (an Epstein-Barr virus negative and HHV-8 negative B cell 
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line) which performed the role of negative controls to rule out any non-specific binding 
of antibodies to cells. 
HIV-1 Serology. Plasma was screened for HIV-1 antibodies using two rapid detection 
kits; Capillus (Cambridge Biotech), and Determine (Abbott Laboratories) according to 
the manufacturer’s instructions. A result was considered positive if one or both of these 
rapid screening assays revealed a positive result. All children born to HIV positive 
mothers were also screened for HIV infection. For children under 18 months of age, early 
infant diagnosis using dried blood spot (DBS) was conducted. If children under 18 
months of age were found to be seropositive but no confirmatory DBS data was 
available, serostatus was based on serology results that were obtained at subsequent 
follow-up visits (>18 months of age). If follow-up visits were not completed, the HIV-1 
result was considered indeterminant.  
Data analysis 
Dataset was built and statistical analysis was conducted using SAS (v9.2) (Cary, NC, 
USA). The crude incidence rate per 100 child-years was calculated by dividing the 
number of new HHV-8 seroconverters by the total number of child-years at risk and 
multiplying by 100.  Seroconverting children contributed HHV-8 free child-years at risk 
until testing positive for HHV-8.  All data was right censored at 48 months.  Cox 
proportional hazards modeling was conducted to explore the strength and significant 
association between HHV-8 infection (outcome) and each individual characteristic 
(covariates). Associations between covariates and outcome were also evaluated to 
identify potential confounders. Hazard ratios (HRs), 95% confidence intervals (CI) and P 
values were calculated to identify risk factors for HHV-8 infection. All comparisons were 
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considered statistically significant at P ≤ 0.05.Variables with a P value ≤ 0.05 in 
univariable analysis were included in a multivariable model utilizing a manual forward 
stepwise selection process, to control for possible confounders and identify independent 
associations. 
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RESULTS 
Index children and members of 1,600 households were screened for study 
eligibility criteria as described elsewhere [12]. As outlined in Figure 1, a total of 270 
index children were enrolled in the current study.  Of the 1023 initial households eligible 
for enrollment, 622 returned for enrollment. There were 254 families unable to return 
with all members of their household, these were considered incomplete and were dropped 
from the study.  The total enrolled were 464 children, comprising 368 households.  Of 
these children, 75 were tested to be HHV-8 positive at the time of enrollment.  Data was 
collected separately from these children, and a cross-sectional analysis was performed as 
described in chapter 3.  Insufficient risk assessments were completed for 119 children, 
excluding them from the study.  Of the remaining 270 children followed, 137 (50.7%) 
children seroconverted to be HHV-8 positive within the four year follow-up time of the 
study, and 133 (49.3%) remained negative.   
Table 1 summarizes the demographics and characteristics of the HHV-8 
seroconverting children, and non-seroconverting children.  Of the seroconverting 
children, at enrollment 11/137 (8.0%) were HIV-1 positive, and 12/133 (9.0%) were 
HIV-1 positive.    
The incidence rate of HHV-8 seroconversion in the total cohort of 270 children 
was 29.94 per 100 child-years, based on a total of 457.57 child-years of follow-up (see 
Table 2). We examined crude incidence rates by primary caregiver and child HIV-1 
status, finding for HIV-1 positive children, incidence rates of 29.19 per 100 child-years, 
and for HIV-1 negative children, incidence rates of 30.01 per 100 child-years. If the 
caregiver was HIV-1 positive, incidence rates were slightly lower, at 25.28 per 100 child-
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years, as compared to if the caregiver was HIV-1 negative, at 34.32 per 100 child-years.  
When only HIV-1 negative children were examined, a similar finding was also noted, 
with incidence rates for HIV-1 positive caregivers at 24.48 per 100 child-years, and for 
HIV-1 negative caregivers at 34.32 per 100 child-years. 
Figure 2 presents the probability curves as obtained from Kaplan-Meier survival 
analysis.  Panel A represents the total cohort, showing the probability of annual HHV-8 
infection occurring over the 4 year time span. This rate of seroconversion is also reflected 
in Table 3, note the age of seroconversion was highly significant when comparing age 
groups of >24M to ≤36M to the reference age of <24M [HR = 0.23 (95% CI: 0.14, 0.37) 
P < 0.001] and >36M to the reference age of <24M [HR = 0.02 (95% CI: 0.007, 0.03) P 
< 0.001].  These findings demonstrate a higher risk associated with an age of <24M with 
HHV-8 seroconversion, and decreasing with age.  Figure 2, panel B shows that the 
probability of males being HHV-8 free is nearing significance (Log Rank P = 0.08).   
 Comparison of HIV status of the child, primary caregiver, or any household 
member was conducted in the group of HHV-8 seroconverting children to non-
seroconverting children. HIV-1 positive status of the mother is nearing significance [HR 
= 0.74 (95% CI: 0.53, 1.05) P = 0.09] (Table 3).  The probability curve as seen in Figure 
2 panel C displays the slightly less probability of a child of an HIV-1 positive caregiver 
to become HHV-8 positive (Log Rank P-value = 0.09). HIV-1 status of any other 
household member was not significant (Table 3).  An HHV-8 positive caregiver showed a 
nearly significant risk [HR = 1.38 (95% CI: 0.98, 1.94) P = 0.06], but most notably 
significant was the increased risk of the child to seroconvert to HHV-8 for every 
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additional household member that is HHV-8 positive [HR = 1.20 (95% CI: 1.06, 1.39) P 
= 0.005] (Table 3).  
No significant associations were found when examining the associations of 
household and living conditions with child HH V-8 seroconversion.  This included 
variables such as, electricity to the house, water source of the house (well water, vs. 
community tap, vs. private water source), number of rooms and sleeping areas in the 
household, number of persons in the household, and number of persons per sleeping area 
(data not shown). 
We found a significant association of the child currently being breastfed with 
child HHV-8 seroconversion [HR = 6.26 (95% CI: 4.02, 9.75) P < 0.0001] (Table 4).  
Also significant was caregiver premasticating food prior to sharing with children [HR = 
3.15 (95% CI: 1.00, 9.98) P = 0.05].  Of interest, all of the adult feeding variables 
assessed, including testing food with tongue to assess the temperature prior to feeding to 
the child, blowing on the food to cool the temperature of the food prior to feeding to the 
child, eating of food with hands from a common bowl at mealtimes, and sharing of eating 
utensils with the child were all significant (Table 4).  Most significant findings included 
other household members testing temperature of food with tongue prior to sharing with 
child [HR = 5.52 (95% CI: 2.00, 15.20) P = 0.0009], primary caregiver blowing on food 
prior to sharing with child [HR = 4.13 (95% CI: 2.37, 7.19) P < 0.0001], and primary 
caregiver sharing of eating utensils with child [HR = 4.28 (95% CI: 2.07, 8.85) P < 
0.0001] (Table 4). 
Table 5 shows several behavioral habits related to sharing sweets and packaged 
drinks that could be potential risk factors for sharing of saliva.  All of the behaviors were 
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highly significant, demonstrating a risk for the child to seroconvert to HHV-8. The 
exception of the primary caregiver sucking on sweets prior to sharing with the child nears 
significance [HR = 2.06 (95% CI: 0.90, 4.74) P = 0.09] (Table 4).  The sharing of food, 
candy, or other sweets was most significant when done with other household children 
[HR = 2.97 (95% CI: 1.57, 5.61) P = 0.0008] (Table 4).  Sharing of packaged drinks such 
as bottled soda was most significant when done with household members other than the 
primary caregiver [HR = 4.87 (95% CI: 2.32, 10.21) P < 0.0001] (Table 4).  Interestingly, 
an association was found with childhood use of a pacifier [HR = 17.62 (95% CI: 4.18, 
74.35) P <  0.0001] (Table 4). 
We observed significant associations with twice per day full-body baths and face 
cleanings for the index child [HR = 4.35 (95% CI: 2.88, 6.57) P ≤ 0.0001] , [HR = 3.95 
(95% CI: 2.47, 6.31) P =  0.0001] respectively, but no significance was found if bathing 
was performed more than twice daily (Table 6).  No significance was found in health 
practice behaviors such as sucking mucus from child’s nose, using saliva to clean child’s 
face, use of Ashton Powder to relieve teething pain, tooth brushing, biting of nails to 
shorten them, or use of Lifebuoy soap for constipation (Table 6). 
Significantly higher hazard was found upon investigating the association of 
childhood interaction variables and child HHV-8 seroconversion, including number of 
playmates (P < 0.0001), and if the number of playmates were under the age of 5 (P < 
0.0001).  Index child spending the night at someone else’s house within the last 6 months, 
and the index child has visiting children spending the night at their house in the last six 
months [HR = 4.35 (95% CI: 2.88, 6.57) P ≤ 0.0001] , [HR = 3.95 (95% CI: 2.47, 6.31) P 
=  0.0001] respectively (Table 7) had significantly higher hazard of seroconversion.  
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However, none of these variables continued to be significant in the multivariable 
analysis. 
In multivariable analysis, independent associations for childhood HHV-8 
acquisition included child age at seroconversion (P < 0.0001), child age at enrollment 
[HR = 2.62 (95% CI:1.64, 4.21) P < 0.0001],  child currently being breastfed [HR = 2.13 
(95% CI:1.31, 3.44) P = 0.002], use of pacifier [HR = 9.00 (95% CI:1.65, 49.19) P = 
0.01], number of daily full-body baths for index child ( P = 0.0006], primary caregiver 
using saliva to clean child’s face, [HR = 38.69 (95% CI:4.50, 332.75) P = 0.0009] , and 
other individuals blowing on food prior to sharing with child [HR = 2.79 (95% CI:1.01, 
7.76) P = 0.05]. Interestingly, although child HIV-1 positive status was not found to be 
significant in the univariable analysis, it became significant when building the 
multivariable model [HR = 2.26 (95% CI:1.19, 4.30) P = 0.013]. 
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DISCUSSION 
  Childhood acquisition of HHV-8 in sub-Saharan Africa occurs at an early age.  
We had previously reported in an earlier study of Zambian mother and infant pairs, 
incidence rates of 13.8 per 100 child-years in children by 48 months of age [3].  Our 
current findings of 29.94 per 100 child-years are more than twice as high as our earlier 
study findings.  This may be explained by the change in HHV-8 serodiagnostic assay 
used.  For this study we performed IFAs with BC-3 cells, a cell line naturally infected 
with HHV-8.  Our earlier study utilized a second confirmatory antibody detection assay 
developed from Sf9 insect cells, expressing 3 key immunogenic recombinant proteins 
[15].  The increased repertoire of antigenic proteins expressed by naturally infected cell 
lines increases the sensitivity of the assay, reportedly between 97% to 100% [16] 
explaining the differences between our findings.  The increased sensitivity can result in a 
loss of specificity, however the overall seroprevalence of our current cohort by the end of 
the study is 50.7%, which is comparable to 20-60% HHV-8 seroprevalence rates in 
young children as reported by other African population studies [10, 17, 18]. 
 Key significant findings in this study include age at seroconversion, significant in 
the univariable analysis (P < 0.00001), and the most significant variable in the 
multivariable analysis (P < 0.00001).  A decreased risk as the child becomes older was 
noted when comparing >24M to ≤36M and <24M [HR = 0.016 (95% CI: 0.09, 0.28) P < 
0.001], and an even lower risk when comparing >36M [HR = 0.006 (95% CI: 0.002, 
0.016) P < 0.001] (Table 8).  These findings along with our total cohort incidence rates 
support that child seroconversion happens very early in age, often before 24 months of 
age. 
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 Findings of current breastfeeding as a risk for HHV-8 seroconversion were 
unexpected, given previous study findings of a lack of HHV-8 DNA in breastmilk [6].  
However, the well documented transmission of herpesvirus family member 
cytomegalovirus in breastmilk, and the reports of other labs isolation of HHV-8 DNA in 
breastmilk makes transmission a possibility [5].  These findings are in contrast to our 
findings reported in chapter 3, in which breastfeeding offered a protection against 
childhood HHV-8 infection at cohort enrollment. Several factors could affect these 
results, such as duration of breastfeeding, whether saliva was used moisten the nipples, 
and age of starting solid foods that this study did not thoroughly investigate. These 
conflicting results warrant further studies, including further behavioral assessments and 
possibly the investigation of neutralizing antibodies in breastmilk. 
 Childhood use of a pacifier was significant in univariable analysis, and remained 
significant in the multivariable analysis.  It is unlikely that the use of the pacifier itself 
provides a risk for childhood HHV-8 acquisition, rather the care and cleaning of the 
pacifier, and the sharing of the pacifier between children.  This is supported by the strong 
significance of sharing of food, candy, sweets and drinks behaviors with child HHV-8 
seroconversion (Table 5).  Interestingly, although behaviors performed by the by the 
primary caregiver were significant contributors to risk of childhood HHV-8 
seroconversion, several variables associated with risk were performed by other household 
members, including other household children. Although interactions with other young 
children did not remain significant in the multivariable analysis, the importance of other 
HHV-8 positive household members’ contribution to HHV-8 transmission may be 
influenced by frequency of sharing, and possibly with other young children due to the 
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nature of close personal interactions among children.  The significance of transmission 
among household members has been confirmed by a study completed in our lab utilizing 
molecular analysis of the K1 gene sequence data of HHV-8 positive individuals from 
nine households in our cohort [19].  Olp et al found that in six of the nine households, the 
child had 100% sequence identify to all household members, supporting that intra-
household transmission occurs [19].  
 The most significant adult feeding behavior remaining in the multivariable model 
was other household members blowing on food prior to sharing with the child.  It is likely 
that this variable is not the only behavior contributing to the risk of childhood HHV-8 
seroconversion, however confounding among feeding variables and sharing of food, 
eliminated many of the significant variables from the univariable analysis in the 
multivariable model.  A wide confidence interval was noted when analyzing using saliva 
to clean child’s face, which likely reflects the very small numbers of primary caregivers 
that responded to participating in this behavior. 
 In the multivariable model as well is the number of daily full-body baths for the 
index child.  These results suggest that the risk is greater than 2x more for a child that has 
baths more than twice daily [HR = 2.18 (95% CI: 1.40, 3.38) P = 0.005].  This result 
could reflect bathing water quality, or shared water.  Since a majority of these households 
do not have water sources on their property, water must be hauled into their households 
on a regular basis from a community water source.  Bathing water is likely shared among 
family members, with the possibility of saliva from family members contaminating the 
water.  However, there is no noted significance when the full body bathing occurs twice 
or more times daily [HR = 0.94 (95% CI: 0.54, 1.62) P = 0.8102].  These findings lend 
112 
 
doubt to the overall significance of the practice of full-body bathing, most likely making 
the significance a spurious finding.   
 The strengths of this study were the size of the cohort and the prospective nature 
of the study.  To our knowledge, this is the first prospective study to examine children 
during such early childhood years for the acquisition of HHV-8.  A similar study by 
Butler et al. demonstrated a significant association with HHV-8 children <14 years of age 
and the sharing of a sauce plate with other household members [11]. Our detailed 
questionnaire enabled us to evaluate whether potential exposures were coming from the 
primary caregivers, other family members within the household, or outside of the 
household, as well as to assess other food sharing variables such as sweets and drinks.  
Butler et al. did not find significance in premastication of food to children and HHV-8 
[11].  However their cohort evaluated children of an older age, up to age 14.  Although in 
our study premastication did not remain significant in multivariable analysis, we did find 
a 3x greater risk for a child to seroconvert to be HHV-8 positive if the caregiver 
premasticates food prior to sharing with the child when performing the univariable 
analysis.  Our unique findings could be due to our investigation of young children. 
Premastication is an uncommon practice in which caregivers chew up food to a 
consistency soft enough for a child just starting to eat solid foods can swallow likely 
practiced between the ages of 6-12 months. Although premastication was not found to be 
frequently performed in our cohort, the amount of saliva that would be needed to soften 
food could pose a risk to the very young child. 
 The weakness of the study was the self-reported nature of the data from the 
behavioral questions.  We believe that the potential for recall bias was limited because 
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the caregivers were not made aware of their HHV-8 status at the time of enrollment and 
counseling and treatment was done regarding transmission of HIV-1 to all study 
participants.  
 In summary, we have demonstrated that behaviors performed in the household 
that could potentially share saliva play a key role in transmission of HHV-8 virus to a 
susceptible child.  Of particular interest are feeding behaviors practiced by adults while 
feeding the index child, such as testing the temperature of food with the tongue prior to 
feeding to a child.  This finding supports a public health risk and the need for education 
of families in endemic areas such as Zambia risks involved with sharing food with young 
children, and needed behavior changes. 
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TABLES AND FIGURES 
 Table 1.  Demographics, HIV-1 and HHV-8 Characteristics of HHV-8 Seroconverters 
and Non-seroconverting Children in Lusaka, Zambia, 2004-2009. 
 
Characteristic 
HHV-8 
seroconverter           
(n=137) 
Non-
seroconverter                     
(n=133) 
Demographics   
Enrollment age of index child (months):        
Range 2-25 2-29 
Mean 12.4 14.2 
Sex of index child:   
   Males 65 76 
Females 72 57 
Number of household members:   
Range 2-8 2-10 
Mean 5.4 4.9 
Education of primary caregiver:   
None 15 11 
Primary school 73 78 
Secondary school  49 44 
HIV-1 serology at enrollment   
Index child HIV-1+ 11/137 (8.0%) 12/133 (9.0%) 
Primary caregiver HIV-1+ 56/137 (40.9%) 65/133 (48.9%) 
≥ 1 other household member HIV-1+   69/137 (50.4%) 71/133 (53.4%) 
HHV-8 serology at enrollment   
Primary caregiver HHV-8+ 66/135a (48.9%) 47/129a (36.4%) 
≥ 1 other household member HHV-8+  (other 
than primary caregiver) 
94/137 (70.8%) 83/133 (62.4%) 
Number of HHV-8+ household members:   
Range 0-7 0-4 
Mean 1.8 1.4 
a Numbers do not match total due to discrepant or unavailable serology at enrollment
  
1
1
7
 
Table 2. Seroincidence rates Child HHV-8 Seroconversion in Lusaka, Zambia, 2004-2009. 
 
Characteristic 
Number of 
Children 
Number 
Seroconverted 
KSHV free child-
years 
Incidence  
(per 100 child-years) 
Total 270 137 457.57 29.94 
Gender     
Male 141 65 255.50 25.44 
Female 129 72 202.06 35.63 
Child HIV Status     
Positive 23 11 37.69 29.19 
Negative 247 126 419.88 30.01 
Caregiver HIV Status 
(total cohort) 
    
Positive 121 56 221.54 25.28 
Negative 149 81 236.03 34.32 
Caregiver HIV Status 
(HIV negative child) 
    
Positive 98 45 183.85 24.48 
Negative 149 81 236.03 34.32 
 
 
 
 
 
  
1
1
8
 
Table 3. Univariable Analysis to Investigate the Association of Gender, Age, Caregiver and Household Characteristics with Child 
HHV-8 Seroconversion in Lusaka, Zambia, 2004-2009. 
Characteristic Hazard Ratio (95% CI) P-value 
Child specific characteristics   
Gender of Index Child (Reference: Females) 0.75 (0.53 - 1.04) 0.09 
Age at enrollment (Ref: <12M) 0.65 (0.46 - 0.92) 0.01* 
Age at Seroconversion:  <0.0001* 
<24M Reference  
>24M to ≤36M 0.23 (0.14 - 0.37) <0.001 
>36M 0.02 (0.007 - 0.03) <0.001 
Caregiver and household member specific characteristics   
Primary caregiver education:  0.95 
No education Reference  
Junior Primary 1.10 (0.55 - 2.26) 0.78 
Upper Primary 1.06 (0.62 - 1.81) 0.85 
Junior Secondary 0.90 (0.51 - 1.61) 0.73 
Upper Secondary 1.09 (0.52 - 2.28) 0.82 
Caregiver HIV status(enrollment) (Ref: Negative) 0.74 (0.53 - 1.05) 0.09 
Child HIV status (Ref: Negative) 0.97 (0.52 - 1.79) 0.91 
Any household member HIV status (Ref: Negative) 0.81 (0.58 - 1.14) 0.23 
Caregiver HHV-8 status(enrollment) (Ref: Negative) 1.38 (0.98 - 1.94) 0.06 
Any other household member HHV-8 status (Ref: Negative)  1.09 (0.76 – 1.57) 0.63 
Increasing number of HHV-8 positive household members 1.2 (1.06 – 1.39) 0.005* 
a Significant at α level of 0.05  
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Table 4. Univariable Analysis to Investigate the Association of Breastfeeding Practices, Premastication, and Adult Feeding 
Behavioral Habits with Child HHV-8 Seroconversion in Lusaka, Zambia, 2004-2009.  
 
Characteristic Hazard Ratio (95% CI) P-value 
Breastfeeding practices   
Child breastfed in the past, currently weaned 1.24 (0.79 - 1.95) 0.34 
Child is currently being breastfed 6.26 (4.02 - 9.75) <0.0001* 
Premastication   
Caregiver premasticates food prior to sharing with 
children 
3.15 (1.00 - 9.98) 0.05* 
Other household members perform the premastication 3.15 (0.44 - 22.71) 0.25 
Adult feeding variables   
Primary caregiver testing temp of food with tongue prior 
to sharing w/ child 
3.39 (1.75 - 6.60) 0.0003* 
Other household members testing temp of food with 
tongue 
5.52 (2.00 - 15.20) 0.0009* 
Primary caregiver blowing on food prior to sharing w/ 
child 
4.13 (2.37 - 7.19) <0.0001* 
Other individuals blowing on food prior to sharing w/ 
child 
4.45 (1.92 - 10.29) 0.0005* 
Eating of food with hands from a common bowl 4.44 (2.05 - 9.60) 0.0002* 
Primary caregiver sharing of eating utensils w/ child 4.28 (2.07 - 8.85) <0.0001* 
Other household members sharing of utensils w/ child 3.53 (1.54 - 8.12) 0.003* 
a Significant at α level of 0.05 
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Table 5. Univariable Analysis to Investigate the Association of Child Behaviors of Sharing Sweets and Drinks with Child HHV-8 
Seroconversion in Lusaka, Zambia, 2004-2009.  
 
Characteristic Hazard Ratio (95% CI) P-value 
Child sharing variables   
Primary caregiver sucking on sweets prior to sharing w/ 
child 
2.06 (0.90 - 4.74) 0.09 
Other household members sucking on sweets prior to 
sharing w/ child 
2.87 (1.38 - 5.97) 0.005* 
Other non-household members sucking on sweets prior to 
sharing w/ child 
3.54 (1.43 - 8.74) 0.006* 
Index child shares food, candy or other sweets with other 
household children 
2.97 (1.57 - 5.61) 0.0008* 
Index child shares food, candy or other sweets with other 
neighborhood children 
3.06 (1.12 - 8.37) 0.029* 
Exchange of food, candy or other sweets from another 
child's mouth to Index child 
2.54 (1.27 - 5.10) 0.008* 
Primary caregiver sharing of packaged drinks w/ child 3.36 (1.54 - 7.33) 0.002* 
Other household members sharing of packaged drinks w/ 
child 
4.87 (2.32 - 10.21) <0.0001* 
Other non-household members sharing of packaged drinks 
w/ child 
7.44 (2.68 - 20.69) 0.0001* 
Neighborhood children sharing of packaged drinks w/ 
child 
5.36 (1.95 - 14.75) 0.001* 
Use of pacifier 17.62 (4.18 - 74.35) <0.0001* 
a Significant at α level of 0.05 
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Table 7. Univariable Analysis to Investigate the Association of Hygiene and Health Practices with Child HHV-8 Seroconversion in 
Lusaka, Zambia, 2004-2009.  
Characteristic Hazard Ratio (95% CI) P-value 
Hygiene practices   
Number of daily full-body baths for index child:  <0.0001* 
Once per day Reference  
Twice per day 4.35 (2.88 - 6.57) <0.0001* 
Twice or more daily 0.83 (0.50 - 1.39) 0.48 
Number of daily face cleanings for index child:  <0.0001* 
Once per day Reference  
Twice per day 3.95 (2.47 - 6.31) <0.0001* 
Twice or more daily 0.54 (0.32 - 0.90) 0.02 
Health practices   
Primary caregiver sucking mucus from child's nose 3.95 (2.47 - 6.31) 0.58 
Primary caregiver used saliva to clean child's face 0.54 (0.32 - 0.90) 0.41 
Use of Ashton Powder to relieve teething pain 1.72 (0.24 - 12.39) 0.06 
Use of toothbrushing to clean teeth 2.30 (0.32 - 16.50) 0.37 
Primary caregiver biting the child's nails to shorten them 3.91 (0.94 - 16.18) 0.45 
Other household members biting the child's nails to shorten them 0.63 (0.23 - 1.71) 0.16 
Lifebuoy soap for constipation 1.72 (0.42 - 6.98) 0.20 
a Significant at α level of 0.05 
  
1
2
2
 
 
Table 8. Univariable Analysis to Investigate the Association of Childhood Interaction Practices with Child HHV-8 Seroconversion in 
Lusaka, Zambia, 2004-2009.  
 
Characteristic Hazard Ratio (95% CI) P-value 
Childhood interaction variables   
Number of playmates:  <0.0001* 
None 2.50 (0.61 - 10.20)  
2-3 1.41 (0.75 - 2.68) 0.29 
>3 0.61 (0.33 - 1.12) 0.11 
Don’t know 8.33 (1.05 - 65.93) 0.04 
Number of playmates under the age of 5  <0.0001* 
None Reference  
2-3 1.16 (0.64 - 2.11) 0.63 
>3 0.52 (0.29 - 0.92) 0.02 
Don’t know 7.14 (0.91 - 55.81) 0.06 
Index child has spent the night at someone 
else's house within the last 6 months 
4.25 (1.55 - 11.63) 0.005* 
Visiting child has spent the night at Index 
child's house within the last 6 months 
7.18 (1.74 - 29.58) 0.006* 
a Significant at α level of 0.05 
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Table 9. Multivariable Analysis to Investigate Independently Associated Risk Factors Associated with HHV-8 Seroconversion in 
Children in Lusaka, Zambia, 2004-2009. 
 
Characteristic Hazard Ratio (95% CI) P-value 
Age at Seroconversion:  <0.0001 
<24M Reference  
>24M to ≤36M 0.16 (0.09 - 0.28) <0.001 
>36M 0.006 (0.002 - 0.016) <0.001 
Age at enrollment (Ref: <12M) 2.62 (1.64 - 4.21) <0.001 
Child is currently being breastfed 2.13 (1.31 - 3.44) 0.002 
Use of pacifier 9.00 (1.65 - 49.19) 0.01 
Number of daily full-body baths for index child:  0.0006 
Once per day Reference  
Twice per day 2.18 (1.40 - 3.38) 0.0005 
Twice or more daily 0.94 (0.54 - 1.62) 0.8102 
Primary caregiver used saliva to clean child's face 38.69 (4.50 - 332.75) 0.0009 
Child HIV status (Ref: Negative) 2.26 (1.19 - 4.30) 0.013 
Other individuals blowing on food prior to sharing 
w/child 
2.79 (1.01 - 7.76) 0.05 
a Significant at α level of 0.05 
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FIGURE LEGEND 
Figure 1. 
 
 
Figure 1. Flow Chart outlining the screening and recruitment of study cohort in Lusaka, 
Zambia, 2004-2009.
Index Children 
n = 464 
HHV8- Children 
n = 389 
HHV8+ Children 
n = 75 
HHV8- Children 
n = 270 
Insufficient records 
n =119 
Seroconverters 
HHV8+ 
n = 137 (50.7%) 
Non-seroconverters 
HHV8- 
n = 133 (49.3%) 
Attended study clinic 
N = 1600 
Completed interview 
N = 1592 
Complete families enrolled 
N = 368 
Did not provide consent 
n = 8 
Incomplete families 
n =254 
Eligible for enrollment 
N = 1023 
Enrolled 
N = 622 
Ineligible 
n = 626 
Did not return for enrollment 
n = 401 
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Figure 2. Results from Kaplan-Meier survival analysis estimating the probability of a child seroconverting to become positive for 
HHV-8 in Lusaka, Zambia, 2004-2009.  Results are represented by the total cohort (n=270) (panel A); males vs. females (panel B); 
human immunodeficiency virus type 1 (HIV-1) infection status of the mother at enrollment (panel C); HIV-1 infection status of the 
child at time of seroconversion (panel D).
126 
 
CHAPTER 5:  DEVELOPMENT OF AN IMMUNOFLUORESCENT 
ASSAY USING RECOMBINANT PROTEINS EXPRESSED IN 
INSECT CELLS FOR THE SCREENING AND CONFIRMATION OF 
HUMAN HERPESVIRUS 8 ANTIBODIES  
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1 Nebraska Center for Virology, School of Biological Sciences, University of Nebraska 
Lincoln, Lincoln, Nebraska 68583 USA;  
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ABSTRACT 
Human herpesvirus-8 (HHV-8) or Kaposi’s sarcoma-associated herpesvirus (KSHV) has 
been linked to all forms of Kaposi’s sarcoma (KS). Most current serological assays to 
detect HHV-8 antibodies have low concordance amongst themselves. To establish a 
sensitive and specific testing strategy to screen for HHV-8 antibodies, three HHV-8 
proteins, ORF65, ORF73 and K8.1A, were expressed using baculoviral vectors in insect 
cells and incorporated into an monoclonal-enhanced immunofluorescence assay (mIFA) 
termed Sf9 3-antigen mIFA. The results with this monoclonal-enhanced mIFA were 
compared to those obtained with a standard mIFA utilizing a HHV-8 infected B-cell line 
(BC3 mIFA). Test sera were obtained from patients with diagnosed KS, HIV-1 infected 
patients at high risk for HHV-8 infection, and healthy controls from a local blood bank. 
Combined use of both assays together had a sensitivity of 94% and a specificity of 96%. 
The performance of these two assays when used together indicates that they may be 
useful for reliable detection of HHV-8 IgG antibodies in a population.  
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INTRODUCTION 
Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma-associated 
herpesvirus (KSHV), is the latest human herpesvirus identified. It has been associated 
with all four clinical presentations of KS (classic, endemic, AIDS related and the 
iatrogenic form) Kaposi’s sarcoma (KS) [6, 15]. HHV-8 has also been detected in 
primary effusion B-cell lymphomas (PEL) and in multicentric Castleman’s disease 
(MCD) [4, 30].  
In the general population, HHV-8 seroprevalence shows marked geographical 
variations. HHV-8 infection is endemic in Africa and the Mediterranean region and in 
non-endemic areas is higher in homosexual men and immunosuppresed individuals [8, 9, 
13, 24]. Routes of transmission are still not well understood but both horizontal and 
vertical transmission are possible [2, 10, 21]. Horizontal transmission can occur by sexual 
and non-sexual routes. HHV-8 seroconversion is observed during adulthood in most 
developed countries, most likely due to sexual transmission, and occurs in childhood in 
endemic areas, most likely due to non-sexual horizontal transmission. HHV-8 DNA has 
been detected in saliva making it to be a potential source of transmission via close 
interpersonal contact [1-3, 9, 18, 22, 31]. HHV-8 DNA cannot be detected in all infected 
individuals therefore; serology is the method of choice in epidemiological studies to 
screen for infected individuals. 
 Development of high performance serologic tests has been achieved to a limited 
degree only due to an incomplete understanding of the known immunodominant proteins, 
lack of well characterized uninfected and infected individuals that serve as controls and 
reported wide variations in antibody titers among infected individuals. While various 
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serological assays have been shown to have variable performance and concordance, 
immunofluorescence assays have been considered as one of the most sensitive assays for 
detecting antibodies against HHV-8 [11, 23, 27]. IFA was one of the first assays to be 
used for the detection of HHV-8 antibodies [20]. Cell lines derived from PEL and 
chronically infected with HHV-8, expressing mainly latent and a low level of lytic 
antigens have been used for latent or lytic IFAs. The level of lytic antigens can be 
increased by induction with tetradecanoyl phorbol acetate (TPA). Using sera of KS 
patients, several proteins have been identified as highly reactive antigens. These include 
open reading frames (ORF) 6, 8, 9, 25, 26, 39, 59, 65, 68, 73, K8.1A and K8.1B [5]. Of 
these proteins, ORF 59, K8.1A, ORF65, and ORF73 have been used in the development 
of various enzyme immunoassays (EIA) and reported to be good candidate antigens [5, 
14, 16, 19, 28, 32]. There are now two commercially available EIAs using whole virus 
lysate and synthetic peptides.  
Here we report the use of a screening strategy for detecting HHV-8 antibodies in 
plasma samples. IFA utilizing Sf9 cells expressing predominant proteins encoded by 
HHV-8 (ORF65, ORF73, K8.1) was used in conjunction with IFA utilizing stimulated 
BC3 cells to obtain a sensitive and specific testing strategy.  
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MATERIALS AND METHODS 
Cell culture: BC-3 cells (ATCC) were grown in RPMI 1640 supplemented with 20% fetal 
calf serum, L-Glutamine, sodium pyruvate, HEPES and D-glucose. Sf9 insect cells were 
maintained as suspension culture in SF 900 II medium (Invitrogen, CA) supplemented 
with 20% fetal calf serum and 1% gentamicin.  
Patient sera: A total of 219 samples were used in this study. Of these, 108 samples were 
collected from patients visiting the Adult Oncology unit at the University of Miami 
Miller School of Medicine. Two KS plasma samples were collected from the University 
Teaching Hospital, Lusaka, Zambia as a part of an ongoing study to investigate HHV-8 
transmission within families. Blood banks at Lincoln, Nebraska and Kansas City, Kansas 
contributed 109 plasma samples. Ethics committee of the Institutional Review Board at 
the University of Nebraska approved the study. All samples were coded and screened 
without knowledge of identity of the patient or the diagnosis. Subsequently, patient serum 
samples were divided into 3 groups. Group A (positive group) consisted of a total of 33 
samples collected from histologically identified KS patients. This group also included 
samples from one PEL and one MCD patient. Group B (high risk group) consisted of 77 
samples collected from HIV-1 positive patients with other cancers (not KS and PEL). 
Group C (negative group) consisted of 109 samples collected from healthy blood bank 
donors with low risk life style behaviors. 
Preparation of BC-3 slides: BC3 cells at a concentration of 7 X 105 per ml were treated 
with tetradecanoyl phorbol acetate (TPA) at a final concentration of 20 ng/ml for 72 hrs. 
The cells were fixed in 4% paraformaldehyde for 20 min at room temperature, washed 
with PBS and permeabilized with 0.1% Triton X 100 for 15 minutes at room temperature. 
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The cells were washed and resuspended in PBS. Approximately 10 4 cells were spotted 
per well onto 12 well teflon coated slides (Electron Microscopy sciences, PA) and stored 
at -80 ºC.  
Preparation of Sf9 cell slides expressing HHV-8 antigens: Recombinant baculoviruses 
expressing glutathione S-transferase (GST) tagged lytic proteins, ORF65 and K8.1A, and 
latent protein, ORF73 (provided by Dr Bala Chandran, Rosalind Franklin University of 
Medicine and Science, Chicago), were used to develop the Sf9-mIFAs. Baculovirus-
infected Sf9 cells expressing GST alone were used as a negative control to detect 
background and nonspecific fluorescence. All baculovirus stocks were titrated and 
infections were initiated separately with the three baculovirus stocks each of which 
expressing one recombinant HHV-8 protein at a MOI of 10. Infected cells were 
monitored daily for viability and cell diameter using Vi-Cell counter (Beckman-Coulter, 
CA). The expression of each protein was evaluated by Western blot analysis with anti-
GST antibody (Santa Cruz Biotechnology, CA) following SDS-PAGE (Figure 1). At 72 
hours post-infection (hpi) cells were harvested, mixed in equal ratio (1:1:1) of viable cells 
and subsequently fixed using the BC3 cell method. This was called as the ‘Sf9 3-antigen’ 
test. All fixed slides were stored at - 80 ºC.  
A modification of the method was also used. At 72 hpi, Sf9 cells infected with 
baculovirus expressing ORF73, ORF65 or K8.1 antigens were harvested, fixed and 
spotted individually on separate slides. This method was used to screen patients for the 
presence of latent or lytic antibodies and is refered to as ‘single-antigen Sf9’ assay 
Monoclonal-enhanced immunofluorescence assay (mIFAs): All serum samples were 
diluted 1:40 and centrifuged at high speed for one minute immediately before being used. 
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All slides were warmed to room temperature, individual serum samples were applied to 
each well and the slides were incubated at 37 ºC for 30 minutes in a humidified chamber. 
The slides were washed (6 times) with PBS and then incubated with mouse anti-human 
IgG monoclonal antibody at 37 ºC for 30 minutes. The slides were washed with PBS 
again and then incubated with goat anti-mouse Cy2 conjugated antibody (Jackson 
Laboratories, City) at 37 ºC for 30 minutes. After washing, the cells were stained with 
0.004% Evan’s blue for 5 minutes, washed and mounted. The procedure of mIFA was the 
same for BC3 and Sf9 slides. 
Criteria for being HHV-8 seropositive: All slides were read by two independent readers 
without knowledge of patient identity, clinical diagnosis, HIV-1 status or the other 
reader’s results. To reduce subjectivity in observing specific fluorescence, slides were 
read independently by two experienced laboratory workers. A sample was considered 
positive if specific fluorescence was observed by both readers. In case of discordant 
results the assay was repeated. On repetition if discordant results were again obtained 
then these patients were considered seronegative. All samples determined to be positive 
by BC-3 mIFA and the Sf9 3-antigen assay were considered positive. If a patient was 
positive on just one assay or negative by both assays, it was considered as HHV-8 
negative. This testing scheme is summarized in Figure 2. 
Statistical analysis: All data was entered and analyzed using SPSS (v15). Kappa statistic 
was computed to determine the concordance between the standard BC3 mIFA and the 
Sf9 mIFA. Sensitivity of detection of HHV-8 antibodies was calculated as: True positives 
/ (True positives + False Negatives). All serum samples collected from reliably diagnosed 
cases of KS, PEL and MCD and found serologically positive by both assays were 
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considered as true positives. Results were considered false negative if serum samples 
collected from these patients were found to be negative by our criteria.  
Specificity was calculated as True Negatives/(True Negatives + False Positives). All 
serum samples collected from healthy blood donors and found serologically negative by 
either assay were considered as true negatives. Results were considered false positive if 
samples collected from these patients were found to be positive. 
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RESULTS 
HHV-8 seroprevalence 
All serum samples were assigned a unique identification number and were 
screened blinded using both mIFAs. Representative mIFA images of a positive and 
negative patient are shown in Figure 3. After serological screening was completed, the 
specimens were divided into 3 groups based on their clinical diagnosis as described in 
Materials and Methods section (Table 1). Using the strategy described in Figure 2, in 
Group A (KS/PEL/MCD) the overall seroprevalence was 93.9%. Two samples were 
considered seronegative, including one sample which tested positive by BC3 mIFA but 
negative by Sf9 3-antigen mIFA and a second sample that was not positive by either of 
the two assays. In Group B, (high risk group) the seroprevalence was 58.4 % with 45 out 
of 77 samples being positive by both assays. The remaining 32 samples were considered 
seronegative. Fifteen out of these 32 seronegative samples (19.5%) were negative by both 
assays. There were 9 (11.7%) and 8 (10.4%) samples that were positive by BC3 and Sf9 
3-antigen assay alone, respectively. In Group C (blood bank donors) both assays detected 
HHV-8 antibodies in only 4 (3.6%) of the patients. The remaining 105 samples were 
considered seronegative. Of these 105 seronegative samples, 2 (1.8%) and 7 (6.4%) were 
positive by BC3 and Sf9 3-antigen assay alone, respectively.  
Latent and lytic antibody profiles 
All samples that were positive on Sf9 3-antigen assay were screened using the 
single-antigen Sf9 method to ascertain the latent and lytic antibody profiles present in 
different groups. Also, we compared the antibody profiles of those samples that were 
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positive with both BC3 mIFA and Sf9 3-antigen assays to samples that were BC3 mIFA 
negative and Sf9 3-antigen positive (Table 2).  
BC3 and 3 antigen positive samples - When mIFAs were performed using ORF65, K8.1 
and ORF73 antigens separately, 74% (23/31) of Sf9 3-antigen and BC3 mIFA positive 
samples in Group A reacted to both latent (ORF73) and lytic (ORF65 or K8.1) antigens. 
Two samples had detectable antibodies against latent antigen only and 6 samples reacted 
to at least one lytic antigen. In Group B, 64% (29/45) of seropositive samples reacted to 
both latent and lytic antigens. There were 8 samples each that reacted only to either latent 
or lytic antigen. In Group C, there was only 1 out of 4 seropositive samples that was 
positive for both latent and lytic antigens. There were 3 samples that were positive for 
lytic antigens only.  
BC3 negative and 3 antigen positive samples - We also wanted to compare the above 
antibody profiles of patients who were negative by BC3 mIFA. We did not find any such 
sample in group A but there were 6 of those samples in Group B.  All these 6 samples 
were negative by BC3 mIFA and had detectable titers to both latent and lytic antigens as 
observed by using the 3-antigen assay. In the same Group there was one sample each that 
was positive for latent or lytic antigens only. In Group C individuals, we observed that 
there was only one sample that was positive for both latent and lytic antigens, but 6 
samples that reacted positively to lytic antigens.  
Concordance, assay sensitivity and specificity  
Kappa value (κ-value) denoting the concordance of BC3 mIFA and Sf-9 3-antigen 
assay was calculated. The overall κ-value of all the 219 samples was 0.75. The sensitivity 
of the screening strategy was then evaluated by using group A (positive group) samples 
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and calculated as described in the Materials and Methods section. Sensitivity of detecting 
positive samples by this combined strategy was 93.9%. The specificity was calculated by 
using group D (blood bank donors) samples. This yielded a specificity of 96.3%. 
137 
 
DISCUSSION 
A large proportion of infected but asymptomatic individuals do not have 
detectable viral DNA in peripheral blood therefore, thus serology is a more reliable 
method to identify infection. But a major hurdle in obtaining clear seroprevalence data in 
a population, understanding the route of transmission and routine monitoring of ‘at risk’ 
individuals, is the lack of a reliable assay that can detect antibodies in human sera.  
Most laboratories use ‘in house’ assays with varying levels of sensitivity and 
specificity and concordance for screening of HHV-8 antibodies [23, 26, 27]. Currently no 
assay is clearly superior in terms of sensitivity and specificity. Our goal was to develop a 
sensitive and specific Sf9 3-antigen IFA that is cost effective and can be used as a 
confirmatory test to validate IFA results using HHV-8 infected cells. In this report both 
BC3 assay and Sf9 3-antigen assay were used in parallel to investigate the concordance 
of the two assays. Given the findings in this report, the Sf9 3-antigen assay can be used in 
tandem as a confirmatory assay with BC3 assay, for screening for HHV-8 antibodies. To 
evaluate the sensitivity and specificity of this testing strategy, we used samples from well 
characterized patients. Both BC3 and Sf9 3-antigen mIFAs are designed to detect HHV-8 
specific IgG antibodies against latent and lytic antigens. ORF73 is the major latent 
protein and encodes for latency associated nuclear antigen (LANA). ORF65 is a lytic 
phase protein and encodes for minor capsid antigen. ORF65 has been reported to be one 
of the immunodominant antigens that can be used for a sensitive serological assay [17]. 
Sf9 3-antigen assay is flexible because it can be expanded to incorporate more antigens if 
needed. Overexpression of the immunodominant proteins also helps to easily identify 
patients having very low titer of HHV-8 antibodies. In Sf9 cells, each antigen can be 
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expressed individually to monitor antibody responses to latent and lytic antigens 
separately. More importantly, the use of a GST-expressing Sf9 cells served as bonafide 
negative controls that were used to check for non-specific binding and fluorescence. Lack 
of matched negative control cells is one of the major drawbacks of assays based on the 
use of BC3 cells. Background or non-specific fluorescence which is commonly found in 
immunofluorescence assays cannot be ruled out when using BC3 or other HHV-8 
harboring cell lines. Populations which have been shown to produce this nonspecific 
reactivity include serum samples from individuals with a high number of sexual partners, 
patients with parasitic infections and among people exposed to a high number of 
pathogens. Residue, sediments or high lipid content can also cause high background and 
was controlled in our assay by centrifugation of each sample immediately before being 
used [7].  
Our criterion to consider a patient as positive in our study was based on two 
immunofluorescence assays. A patient was considered positive if the plasma sample gave 
specific fluorescence at a dilution of 1:40 by both IFAs. While this strategy increases the 
specificity of detecting HHV-8 antibodies it may decrease the sensitivity of detection. By 
using this testing strategy we could detect HHV-8 antibodies in 94% of clinically 
diagnosed cases of KS, PEL and MCD. In the positive patients with KS there was one 
patient that was negative by both BC3 and Sf9 IFAs. This patient has undergone 
antiretroviral treatment after the development of KS, which could have suppressed the 
viral load and led to complete seroreversion for HHV-8 antibodies by then. Seroreversion 
has in fact been documented in patients after treatment and regression of symptoms [25]. 
CD4+ cell count data was not available to help gauge the level of immunosuppression 
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which may also help explain the unexpected HHV-8 seronegativity. It is possible that the 
sensitivity of both the assays was too low to detect the very low antibody titer in this 
patient. One sample in the positive group was positive by BC3 mIFA but negative by Sf9 
mIFA. This could be non-specific fluorescence shown by BC3 mIFA and cannot be 
reliably confirmed because of lack of matched negative cell line. It is also likely that for 
this patient none of the three antigens that were expressed in Sf9 cells were eliciting an 
immune response and further underscores the importance of using multiple antigens for 
screening. This suggests that there is a need for identification and incorporation of more 
antigens for routine screening of patients. 
We had chosen the blood bank donor group as our truly negative controls because 
they are selected for minimal behavioral risk. Using this testing scheme, we found a 
seroprevalence of 3.7% in this group. This is not surprising because a low seroprevalence 
of about 3% has been reported in United States blood donors [23]. We observed a similar 
seroprevalence in the blood bank donors which we had assumed to be negative. In our 
case it reduced the specificity (96%) of this testing strategy. The lack of a “gold standard” 
serological assay that can reliably identify patients that are truly infected versus those that 
are uninfected makes it difficult to test the accuracy of the assays currently in use. 
Group B patients were included as a test group. The seroprevalence in Group B 
samples was within the expected range. HIV-1 infected patients from North America 
have been reported to have HHV-8 seroprevalence in the range of 20-50% [12, 20, 29]. 
We observed a similar seroprevalence rate of 58.4% in this group. The antibody profile 
showed that 82% of the seropositive samples had lytic antibodies which is indicative of 
active replication and has been shown to be a risk factor for development of KS. No 
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follow-up was available for these patients and we do not know if any of these developed 
KS.  
This assay could have some other drawbacks. It is more labor intensive than EIA 
and reading of slides can be subjective. We tried to reduce the subjectivity effect by 
employing two readers who read all the slides independently. EIA’s have frequently 
employed KS patients to obtain cutoff values for optical density. This approach might 
exclude asymptomatic individuals who are seropositive and frequently have very low 
titer of HHV-8 specific antibodies. This method has proved to be adequately sensitive in 
detecting HHV-8 specific antibodies from asymptomatic children and adults in Zambia; 
an endemic region for HHV-8 infection (manuscript submitted). In our experience most 
of the asymptomatic individuals in this cohort in Zambia have very low antibody titer and 
EIA’s utilizing high cutoff values are not suitable for conducting such epidemiological 
studies. We believe that our stringent criteria of detection may still be underestimating 
the number of seropositive cases and reducing the level of sensitivity. But this scheme 
increases the specificity of detection of HHV-8 antibodies by excluding false positives. 
For this study we did not test these patient samples to other known ubiquitous 
herpesviruses. Our observations from other adult patient samples from similar locations 
have shown a very high seroprevalence. 
Reliable serological assay could be a useful tool in the accurate monitoring and 
diagnosis of HHV-8 infection. In the absence of a gold standard this strategy has proven 
helpful in conducting seroepidemiological studies in an endemic area. A better 
understanding of HHV-8 antibody response is required to perfect the current serological 
testing strategy. In conclusion, we describe a new serological approach to screen patients 
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for the presence of HHV-8 antibodies that is sensitive and specific and reduces the 
chances of detecting false positives. Finally, further refinement of this approach to 
incorporate more antigens is ongoing.  
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TABLES AND FIGURES 
Table 1: Seroprevalence of HHV-8 antibodies in positive control, high risk and blood 
bank donors.  
 
 Positive group High risk group Negative group 
 n (%) n (%) n (%) 
HHV-8 Positive    
BC3+/3-antigen+ 31 (94.0) 45 (58.4) 4 (3.7) 
HHV-8 Negative    
BC3+/3-antigen- 1 (3.0) 9 (11.7) 2 (1.8) 
BC3-/3-antigen+ 0 8 (10.4) 7 (6.4) 
   BC3-/3-antigen- 1 (3.0) 15 (19.5) 96 (88.1) 
 
Note: Positive sign (+) refers to patients who tested positive and negative sign (-) refers 
to patients who tested negative by that assay. 
 
 
  
1
4
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Table 2: Antibody profiles of all Sf9 3-antigen positive samples, against latent (ORF73) and lytic (ORF65 or K8.1) antigens.  
 
 
 
 
 
 
 
Note: Positive sign (+) refers to patients who tested positive and negative sign (-) refers to patients who tested negative  
 
 
Latent Lytic 
 Positive group  High risk group  Negative group 
BC3+ BC3-  BC3+ BC3-  BC3+ BC3- 
+ +  23 .  29 6  1 1 
+ -  2 .  8 1  . . 
- +  6 .  8 1  3 6 
Total  31 0  48 8  4 7 
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FIGURE LEGENDS 
Figure 1. 
 
 
Figure 1. Western blot analyses of ORF65, ORF73 and K8.1A proteins expressed in Sf9 
insect cells. Infected cells were harvested at 72 hours post-infection and lysed by 
sonication. Specific proteins were detected by using anti-GST antibodies: Lanes 1-3, 
ORF65 (48 kda), ORF73 (>150 kda) and K8.1A (52 kda), respectively. Arrows indicate 
the expressed proteins.  
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Figure 2. 
 
Figure 2: Scheme followed to screen patients for HHV-8 antibodies and determining 
their serostatus.  
  
Seropositive patient 
Patient plasma 
BC3 assay Sf9 3-antigen assay 
Sf9 3-antigen assay BC3 assay 
Screened by both 
assays 
- + + - 
- + + - 
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Figure 3. 
 
 
Figure 3. Representative staining patterns of mIFAs of ORF65, ORF73 and K8.1A 
proteins expressed in Sf9 insect cells and of BC3 cells using a positive (KS)  (left 
column) and a negative (blood bank donor) (right column) patient sera.  
by that assay. 
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CHAPTER 6:  CONCLUDING REMARKS 
 
  Human herpesvirus-8 is the etiologic agent for several malignant pathologies, 
including body cavity-based B-cell lymphoma (BCBL), primary effusion lymphoma 
(PEL), multicentric Castleman’s disease, and Kaposi’s sarcoma (KS).  The onset of the 
HIV epidemic in sub-Saharan Africa where HHV-8 is endemic has led to an increase in 
KS incidence from 3.2% to 19%, making KS the most common tumor in children in sub-
Saharan Africa [1-3].  Although several epidemiologic studies have examined 
transmission risk factors in adults, there is a paucity of data about the transmission of 
HHV-8 to susceptible children.   
Several studies have implicated saliva as the mode of perinatal transmission, as 
HHV-8 DNA is readily isolated from buccal swabs and whole saliva [4, 5]. In early 
childhood, close contact with caregivers, household feeding practices, health care 
practices, and child-rearing behaviors all are possible sources of saliva exposure. In 
Zambia, additional traditional and cultural practices also can increase saliva sharing [6].  
Our overall hypothesis is that household behaviors that expose the child to saliva increase 
the risk of transmission of HHV-8 to the child.  To test our hypothesis, we launched the 
Zambia KS-HHV-8 Study, a large prospective cohort study in Lusaka, Zambia, to follow 
young children and their households, investigating incidence and associated risk factors 
in early childhood HHV-8 infection.   
       In the undertaking of any large epidemiologic investigation, careful planning of 
study design is essential to attain reliable results.  In chapter 2, the study design, the 
methodology in cohort development, the recruitment, screening and enrollment are 
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described in detail.  Loss to follow-up is a great concern in large studies and was a 
challenge in our earlier Zambian study of mother and infant pairs [7].  To minimize this, 
we utilized community workers to assist in recruitment process, follow-up and participant 
retention.  In total, 1,600 households were screened and 368 households comprised of 
464 children were enrolled.   
       Chapter 3 examines the seropositivity of HHV-8 in children at enrollment of the 
cohort, and associated behavioral risks. This is a cross-sectional study of 75 children 
found to be HHV-8 positive and their households.  Key findings were the risk for HHV-8 
infection included increasing number of HHV-8 positive household members [OR 2.5 
(95% CI: 1.9, 3.3) P < 0.01] and having a primary caregiver who tested the temperature 
of food with their tongue prior to feeding the child [OR 2.4 (95% CI: 1.93, 3.30) P 
=0.01]. Breastfeeding was protective against infection with HHV-8 for children [OR 0.3 
(95% CI: 0.16, 0.72) P <0.01]. 
       In chapter 4 we looked longitudinally at HHV-8 negative children, examining 
incidence of HHV-8 infection, and the household and behavioral risks associated. Most 
significant independent risk factors for HHV-8 seroconversion included age at 
seroconversion (P < 0.0001), age at enrollment [HR 2.62 (95% CI: 1.64, 4.21) P < 0.001],  
child currently being breastfed [HR = 2.13 (95% CI:1.31, 3.44) P = 0.002], use of pacifier 
[HR = 9.00 (95% CI:1.65, 49.19) P = 0.01], child HIV-1 status [HR = 2.26 (95% CI:1.19, 
4.30) P = 0.013], and other individuals blowing on food prior to sharing with child [HR = 
2.79 (95% CI:1.01, 7.76) P = 0.05].  
       This dissertation also included a study on developing an analytical assay to detect 
anti-HHV-8 antibodies.  There is no gold standard for diagnostic assays for HHV-8.  
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Wide variations reported in population prevalence studies for HHV-8 are often attributed 
to the different diagnostic assays used [8].  As a part of launching the study in Zambia we 
have to adapt the current assays to the study setting. This study describes the 
development of a monoclonal immunofluorescent assay protocol using an HHV-8 
infected B cell line (BC3), and a recombinant protein expressed in Sf9 insect cells to 
screen patient plasma for HHV-8 antibody detection. A sensitivity of 94% and a 
specificity of 96% is reported. 
       Overall, this dissertation describes the development of an epidemiologic study to 
examine HHV-8 transmission within households, and the association of transmission of 
HHV-8 to a susceptible child with behaviors that expose a child to saliva.  Taken 
together, the studies in this report suggest that associations between feeding habits that 
expose a child to saliva are associated with the risk of early childhood acquisition of 
HHV-8. Although our work supports that the most significant risk of HHV-8 
transmission to a susceptible child lies with the primary caregiver, we know that 
transmission can also occur with other household members and even outside of the 
household [9].    
       Although other studies have looked at HHV-8 transmission in families, the studies 
reported here are unique and have several strengths.  The importance of longitudinal 
studies in HHV-8 epidemiologic studies cannot be understated.  It is well documented 
that antibody titers can vary significantly across time, making antibody levels drop below 
detection limits of most antibody detection assays [7].  This affects the validity of point 
prevalence studies in HHV-8.  In our study, trends across time could be monitored to help 
insure accuracy of diagnostics.   
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Another strength of our study is the cohort design.  We enrolled very young 
children, as young as 2 months of age to ensure enrollment of HHV-8 negative children.  
Children become HHV-8 positive at a very young age, and investigating the influence of 
behaviors as they occur is important in avoiding recall bias.  Another important 
component of our study is that our cohort was comprised of complete households. In 
resource-poor counties, households often move frequently, and family members may 
leave and reenter households due to work situations. Moreover, Zambian families 
continue to be affected by the high mortality rates secondary to AIDs. Households are 
often comprised of extended family as caregivers, or children from extended families 
which may move in and out of the household on a frequent basis.  Maintaining our cohort 
and following complete households for 48 months allowed us to collect valuable 
information for epidemiologic analysis. The final strength of our study is the detailed 
questionnaire, allowing us to assess not only how HHV-8 transmission may occur, but if 
the source is from the primary caregiver, other household members, or from 
neighborhood children.  
A surprising but interesting finding in our studies is the seemingly contradictory 
effect of breastfeeding.  In chapter 3, we report that breastfeeding was protective; 
however in chapter 4 in looking at the longitudinal cohort, breastfeeding became a risk 
for transmission.  We believe that this is an important question that should be explored 
further.  It warrants exploring breast milk further for viral presence, and also 
investigating for maternal antibodies that may be neutralizing. Future behavioral studies 
are warranted, such as use of saliva on the nipples prior to feeding the child, or presence 
of a confounding factor such as initiation of solid foods while breastfeeding. 
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In summary, we have demonstrated that HHV-8 presence in the household plays a 
key role in transmission of the virus to a susceptible child.  This likely occurs through 
saliva sharing during behaviors such as testing the temperature or blowing on food before 
sharing to children.  
The significance of this project is that understanding the possible source and route 
of transmission of HHV-8 virus should lead to developing strategies to facilitate 
behavioral changes to decrease the incidence of infection in children and the development 
of KS. This supports the need for increased public awareness and education regarding 
risks of viral transmission with child-feeding behaviors that expose children to saliva.  
These findings have potential implications in public health, in identifying populations at 
highest risk for evaluation, and potentially for possible future vaccine studies. 
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